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Abstract 
 Stroke is one of the most common, and damaging, neurological afflictions.  
Stroke causes widespread and variable chronic effects, due to the limited regenerative 
ability of the adult brain.  Altered gene expression induces neuronal changes 
necessary for plasticity-dependent recovery, effects which can be enhanced by growth 
hormone-based pharmaceuticals.  These processes are driven by alterations in the 
informational capacity of the genome – changes driven by epigenetic regulators.  
Following experimental strokes, and treatment with EGF and EPO, this study shows 
that two epigenetic regulatory mechanisms, DNA methylation and microRNA 
regulation, are significantly altered, both in treated and untreated animals.  
Specifically, treatment induces a net global suppression of miRNA activity, which 
appears to modify the physical behaviour of neurons in domains ranging from 
plasticity and memory formation, growth and replication, and potentially even to 
neurological disease signalling.  The confirmation of epigenetic alterations following 
a stroke indicates a future role for epigenetic neuro-pharmacology in stroke 
management. 
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1 - Introduction 
 Cerebrovascular accident, or, as it is more commonly known, stroke, is one of 
the most widespread and common human medical afflictions.  Briefly put, stroke is a 
disruption of neurological function caused by the interruption of blood supply to the 
brain.  The resultant hypoxic conditions lead to cell damage and death, and result in a 
loss of neurological function.  According to the most recent data, stroke is the second 
most common cause of death globally (accounting for some 9% of all human deaths 
(Donnan, Fisher, Macleod, & Davis, 2008)), and as the population of the developing 
world ages, it may soon overtake heart attack as the most common cause (Feigin, 
2005).  Furthermore, and perhaps more relevant to the purpose of this work, stroke is 
the leading cause of adult disability in both the United States and Europe, estimated 
to account for 4% of all direct health care costs in industrialised nations (an estimated 
40.9 billion USD per year) (Donnan, et al., 2008).  Given the vast cost to both our 
health care systems and our life expectancies, stroke has become a major focus of 
medical neuroscience research, with research concentrating on three major areas.  The 
first of these, as always, is prevention.  Stroke rates are in decline in the industrialised 
world, due to both our greater understanding of the risk factors associated with it 
(high blood pressure, cigarette use, and the like) and our improving quality of life 
(Strong, Mathers, & Bonita, 2007).  However, increasing life expectancy in most 
regions of the world mitigates the effects of preventative research somewhat, as an 
aging population will undoubtedly experience more and more strokes.  The second 
major thrust of stroke research, acute treatment, seeks to reduce the physiological 
impacts of the damage caused by the stroke, by either removing the source of the 
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stroke (using for example, thrombolytic ‘clot buster’ drugs such as Tissue 
Plasminogen Activator (TPA)("Tissue plasminogen activator for acute ischemic 
stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke 
Study Group," 1995)) or simply placing stroke patients in an environment containing 
sufficient medical expertise (Langhorne, Williams, Gilchrist, & Howie, 1993).  Acute 
therapy, though, has a major drawback – it has limited effectiveness outside of very 
precise therapeutic windows.  Studies indicate that TPA therapy is only effective 
within three hours of stroke onset (Cronin, Weisman, & Llinas, 2008), and aspirin, 
which has shown considerable promise as an acute treatment, within 48 hours 
("CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients 
with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative 
Group," 1997).  Given these factors, it is unreasonable to presume that we will ever 
‘stop stroke in its tracks’.  Instead, stroke research consists of a third major focus, 
which will be the topic of this work: methods whereby the damage caused by stroke 
can be compensated for, and perhaps even repaired. 
 Before examining options for neural recovery and repair, it is important to 
note that stroke is divided into two clinical subtypes, both of which cause similar 
symptoms, but present different pathology.  Ischemic stroke (which accounts for 
roughly 80% of all clinical strokes (Grysiewicz, Thomas, & Pandey, 2008)) results 
from the occlusion of an afferent blood vessel and the subsequent reduction of the 
blood and oxygen supply to the affected brain regions (Donnan, et al., 2008).  
Hemorrhagic stroke, on the other hand, is caused by ruptures in afferent blood 
vessels, leading to hypoxia-based cell death and presentation of stroke symptoms 
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(Auer & Sutherland, 2005).  The difference between these subtypes is critical in the 
acute therapeutic window, as their successful clinical management is vastly different 
(Donnan, et al., 2008).  It remains to be seen whether a recovery based treatment 
strategy is as sensitive to the underlying pathology of a stroke. 
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2 – Ischemic Stroke 
 2.1 – Causes, Risk Factors 
 There are a number of factors that are capable of contributing to the onset of 
an ischemic stroke.  An ischemic event can be caused by anything ranging from a 
thrombolytic blockage of an artery to the collapse of arterial walls due to hypoplasia 
or arterial weakening. It is impossible to conclude that a certain constellation of 
physical markers is directly responsible for ischemic events, but a number of common 
factors can be identified from the literature.  Perhaps the most important factor is 
atherosclerotic vascular disease, as it has been shown to be one of the key 
contributors to both myocardial and cerebral ischemia (Adams, 2009).  Indeed, most 
of the risk factors associated with stroke (hypertension, hyperlipidemia, and diabetes 
mellitus) are identical to those associated with atherosclerosis.   
 It has also long been known that migraine (and especially migraine with aura 
(Pezzini, et al., 2009)) is highly correlated to incidence of ischemic stroke.  Though a 
direct causative link between the two has yet to be shown (Katsarava, Rabe, & 
Diener, 2008), there are a number of pathological factors of migraine that could either 
trigger the onset of a stroke or render the neurovascular system more sensitive to 
infarct.  Migraine triggers a specific pattern of cortical spreading depression (a 
phenomenon first described in 1944 as a response to brain injury (Leao, 1944)) that 
originates in the occipital lobe and spreads through the cortex (Welch, Cao, Aurora, 
Wiggins, & Vikingstad, 1998).  The depolarisation caused by this phenomenon 
induces, among other things, a reduction in cerebral blood flow (Friberg, Olesen, 
Lassen, Olsen, & Karle, 1994), which increases the risk of migrainous infarction.  
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Migraine also appears to have the potential to induce hypercoagulability, by 
increasing the circulating levels of platelet-activating factor (PAF) (Sarchielli, et al., 
2004) and (vWF) (Cesar, Garcia-Avello, Vecino, Sastre, & Alvarez-Cermeno, 1995).  
In addition to its possible capability to directly trigger stroke, there is also a growing 
body of evidence that the physical stress of a migraine increases the risk of 
developing non-migrainous stroke, possibly by causing long-term permanent 
endothelial disruption (Tietjen, 2007) (which would be supported by Cesar et al.’s 
findings (Cesar, et al., 1995), as vWF is a biomarker for endothelial damage).  In 
addition, many of the conditions underlying cardiovascular disease are co-morbid 
with migraine (Yoon, et al., 2005), suggesting that migraine and risk for ischemia 
may be manifestations of the same pathology. 
A recent study by Chuang et al. (Chuang, Liu, Pan, & Lin, 2007) shows a 
correlation between a relatively uncommon birth defect of the circle of Willis and an 
increased risk for ischemic stroke caused by anterior cerebral artery (ACA) occlusion.  
The birth defect, hypoplasia of the A1 segment of the ACA, was shown to correlate to 
both increased risk for ipsilateral hemispheric borderline stroke, and, unexpectedly, 
an increase in the presence of small-artery atherosclerosis in the ipsilateral striatum, 
indicating that weaknesses in afferent arteries may heavily contribute to the ischemic 
weakness of their distal counterparts. 
  
2.2 – Pathology 
A stroke is composed of two distinct regions, the ischemic core and the 
penumbra, which present highly different pathologies, time courses, and prospects for 
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therapeutic intervention.  The ischemic core is comprised of the region most directly 
affected by loss of circulation and so, consequently, experiences the most drastic 
impact in terms of tissue damage.  A reduction in cerebral blood flow to below 0.2 
mL/g/min is enough to cause highly metabolically active neural tissue to deplete its 
oxygen and metabolite reserves in under a minute, at which point mitochondrial 
respiration ceases (Warlow, 2001).  Anaerobic respiration cannot sustain the level of 
ATP production necessary for neuronal function, so the cells rapidly acquire an ATP 
deficit.  This results in the disruption of major cellular functions, most notably 
membrane transport.  Neural tissues maintain an exquisitely regulated balance of ions 
and membrane potential, which is critical for cellular function and survival.  
Disruption of ion transport pumps causes cellular depolarisation and Ca2+ influx, 
which triggers a burst of excitatory glutamate neurotransmission (Mergenthaler, 
Dirnagl, & Meisel, 2004).   The burst of glutamate is sufficient to activate AMPA and 
NMDA receptors, triggering further membrane depolarisation and calcium influx.  
Severe ATP deficits also disable glutamate re-uptake mechanisms, creating a two-
fold overload of excitatory neurotransmitter (both in its overabundance and its 
persistence) (Lo, Dalkara, & Moskowitz, 2003). This feeds back into overstimulation 
of the AMPA receptor which causes efflux of Na+ and Cl- ions into the intracellular 
space, creating an osmotic gradient which forces water into the cell.  In conditions of 
extreme ATP deficits, the excitotoxic feedback loop is capable of generating an 
osmotic gradient sufficient to induce lysis in cells.  This rapid, uncontrolled cell 
death, necrosis, is the hallmark of the ischemic core, and is generally considered to be 
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beyond the reach of acute therapy, as the cells rupture and die within minutes of 
onset. 
In regions directly adjacent to the core, however, a slightly different sequence 
of events unfolds, the severity of which is dependent on the distance from the primary 
infarct (Moustafa & Baron, 2008).  Due to residual circulation in unaffected blood 
vessels, this surrounding region, termed the penumbra, does not experience acute 
cellular oedema and lysis, due to the preservation of some activity by membrane 
transport pumps (Hossmann, 2006).  Instead, it undergoes a characteristic sequence of 
events known as the ischemic cascade (Hinkle & Bowman, 2003).  The initial 
sequence of events of the ischemic cascade is qualitatively similar to that of the 
necrotic pathway, but the dysregulation of ionic balance never achieves the critical 
point necessary to induce osmotic lysis.  Instead, the milder hypoxic climate of the 
penumbra causes these cells to slowly degrade, showing many similarities to 
apoptosis1.  Penumbral cells continue to accumulate abnormally high levels of Ca2+, 
which triggers two distinct processes – mitochondrial apoptosis control, and free 
radical accumulation.  In addition, recent evidence suggests that post-ischemic 
apoptosis is also mediated by FasL mediated death receptor signalling (Broughton, 
Reutens, & Sobey, 2009). 
 
 
                                                 
1 Hypoxic stress still brings with it some features of necrosis, leading Lo et al. (Lo, et al., 2003) to term 
the cell death process in the penumbra ‘aponecrosis’.  For purposes of this review, the apoptotic-like 
behaviour of penumbral cells will be referred to as ‘apoptosis’ in order to make a clearer distinction 
between the ‘slow death’ experienced by the penumbra and the rapid lysis in the core.  It should be 
noted, however, that the speed of stroke-induced cell death (and its similarity to either necrosis or 
apoptosis) is determined by its distance from the central infarct, and its resultant position on a hypoxic 
gradient. 
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2.2.1 – Mechanisms of Cell Damage in the Penumbra 
Intracellular calcium levels activate an intrinsic apoptotic pathway by 
activation of calpains.  In addition to caspases-8 signalling caused by the extrinsic 
apoptotic pathway (detail below), these signals result in the cleavage and activation of 
BCL-interacting domain (BID, or tBID in its truncated, active form), a member of the 
BCL-2 family of proapoptotic proteins (Sugawara, et al., 2004).  tBID binds and 
targets the outer mitochondrial membrane, activating other proapoptotic proteins such 
as Bak, Bax, Bad, and Bcl-XS (Sugawara, et al., 2004).  These signals are presumed 
to induce release of apoptogenic factors from the intermembrane space through an 
event known as the mitochondrial permeability transition (mPT)(Zoratti & Szabo, 
1995).  The mPT is a Ca2+ and oxidant-mediated opening of a pore in the inner 
mitochondrial membrane leading to severe disruption of mitochondrial function and 
massive release of free radicals, divalent cations, and any number of enzymes that 
contribute to cell death, including endonucleases, ATPases, and phospholipases 
(Mergenthaler, et al., 2004; Zoratti & Szabo, 1995), all of which contribute to the 
ongoing damage of the hypoxic environment.  In addition to the above, the mPT also 
induces release of mitochondrially-sequestered Cytochrome c (Elmore, 2007), which 
initiates the caspase-dependent apoptotic pathway.  Cytochrome c and its co-factors, 
procaspase-9 and apoptotic protein-activating factor-1 (Apaf-1) assemble into a 
structure termed the ‘apoptosome’ (Love, 2003), causing procaspase-9 to activate 
caspase-9 (Elmore, 2007), which subsequently activates caspase-3, causing its 
translocation to the nucleus and initiation of the final stages of apoptosis.  One of the 
primary targets of caspase-3 is poly(ADP-ribose) polymerase (PARP) – which, once 
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inactivated, contributes to the accumulation of genomic damage and eventual 
apoptotic cell death (Broughton, et al., 2009).  A study by Endres et al. (Endres, 
Wang, Namura, Waeber, & Moskowitz, 1997) shows that pharmacological re-
activation of PARP can reduce the size of the penumbra, indicating that PARP-
mediated apoptosis plays a role in ischemic neuronal apoptosis and final infarct size. 
In conjunction with the ionic imbalances, enzymatic activity and physical 
degradation of the neuron, hypoxic by-products (such as anaerobic respiration, the 
mPT, and calcium accumulation) also induce the accumulation of free radicals, which 
are capable of causing massive, irreversible cellular lesions (Durukan & Tatlisumak, 
2007).  Free radicals can cause damage to virtually any cellular component, including 
but not limited to genomic DNA, the nuclear and cellular membranes, and other 
organelles (Rao, 2009).  The un-targeted nature of this type of damage can be 
especially negative, as particular free radical lesions (such as a ruptured cell 
membrane) may cause cells to simply lyse instead of apoptose, which has the 
potential of causing a necrotic chain reaction.  Necrosis is a relatively uncontrolled 
form of cell death, during which a variety of enzymes and neurotransmitters are 
released into the intracellular space. The risk of a chain reaction occurring develops 
because these enzymes are capable of triggering membrane damage and 
excitotoxicity in neighbouring cells, potentially killing them and releasing their 
complement of enzymes into the intracellular medium.  Free radicals also are a major 
source of damage in reperfusion injury, as discussed below. 
Extracellular signals also play a role in the third type of death signalling, the 
FasL mediated extrinsic apoptotic pathway (Broughton, et al., 2009).  In addition to 
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cell damage, ischemia also triggers a variety of changes in gene expression, including 
the hyperactivity of the Forkhead1 transcription factor (Sugawara, et al., 2004), which 
produces high quantities of the extracellular Fas ligand (FasL), a protein that begins 
accumulating in the extracellular space.  FasL will bind to the Fas membrane 
receptor, recruiting Fas-Associated Death Domain (FADD), which possesses an N-
terminal motif capable of activating procaspase-8 (Love, 2003).  This entire complex 
is referred to as the death-inducing signalling complex (DISC).  DISC acts by 
recruiting and cleaving caspase-8, which activates it.  Caspase-8 is capable of 
triggering apoptosis through two different downstream targets – it can cleave BID to 
initiate intrinsic apoptotic signalling, or it can directly activate caspase-3 to trigger 
nuclear apoptosis (Cho & Choi, 2002). 
Unfortunately for the patient, once the stroke begins, time is of the essence.  
The apoptotic pathway takes anywhere from one to three hours (Cronin, et al., 2008) 
to fully kill the cells in the penumbra, and during this time, reperfusion (restoration of 
blood flow) can trigger cell survival.  This is the time when treatment with TPA and 
other thrombolytic drugs can have the greatest impact, as over 50% of the volume of 
a final stroke lesion originates from the penumbra (Mergenthaler, et al., 2004).  
However, there are three more sources of potential damage that the penumbra must 
endure before the patient is truly out of danger – the inflammatory response, the 
threat of hemorrhagic transformation, and reperfusion injury. 
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2.2.2 – Inflammation and the Immune Response 
Ischemic stroke, like nearly all injuries, triggers a response from the immune 
system.  Within a few hours of stroke, there is increased immune activity near the 
infarct, including infiltration of circulating neutrophils and monocytes, and activation 
of microglia, astrocytes and endothelial cells in the damaged region (Muir, Tyrrell, 
Sattar, & Warburton, 2007).  Though this is a standard response to injury, there is 
evidence that inflammatory responses may exacerbate the damage caused by the 
initial stroke.  Tissue damage initiates immediate up-regulation of interleukin 1 (IL-1) 
expression (Touzani, Boutin, Chuquet, & Rothwell, 1999) as well as C-reactive 
protein (CRP) activity, two inflammatory cytokines which are capable of stimulating 
cell death through the MAP kinase and NFκB pathways.  Though its direct role in 
neuronal damage has yet to be determined, there are a number of potential 
mechanisms through which IL-1 could induce neurodegeneration, including its role in 
proapoptotic signalling, generation of prostaglandins, expression of adhesion 
molecules, increased expression of acute phase proteins, stimulation of immune cell 
invasion, and activation of complement.  All of these mechanisms have been 
implicated in neuronal damage (Touzani, et al., 1999).  Simple recruitment of 
additional immune cells presents a major problem in the brain – the infiltration of 
large numbers of these cells can physically block the narrow blood vessels of the 
brain, preventing reperfusion even if the initial arterial blockage has been removed 
(Barone, et al., 1992).  In addition, the recruitment of phagocytotic immune cells can 
cause further cell death; these cells engulf and destroy ‘damaged’ neurons as part of 
their typical immune behaviour. 
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Contrary to the deleterious role played by up-regulation of pro-inflammatory 
cytokines like IL-1, the immune response to stroke also induces modulation of anti-
inflammatory cytokines such as TGF-β1 and IL-10 (Mergenthaler, et al., 2004).  
Experimental over-expression of anti-inflammatory factors has been shown to have a 
neuroprotective effect (Strle, et al., 2001), indicating that the immune response plays 
a very complex role in the ongoing damage to the penumbra.  Furthermore, a recent 
study by Suzuki et al. (Suzuki, Tanaka, & Suzuki, 2009) implicates IL-6, a pro-
inflammatory cytokine, as both a contributor to inflammatory damage in the acute 
phase of ischemia, and as a neurotrophic / neuroprotective mediator in later phases.  
This suggests that the complexity inherent in an immune response may provide an 
interesting arena for therapeutic intervention during both the therapeutic and post-
ischemic time points, which bears examination in other studies. 
 
2.2.3 – The Blood - Brain Barrier 
Infarction can disrupt the integrity of the blood-brain barrier by causing 
damage to the cellular matrix components responsible for its structural stability.  
Induction of matrix metalloproteases (MMPs) in the 1-3h post-ischemic window, 
especially MMP2 and MMP9, has been shown to cause damage to basal lamina and 
the astrocytes and endothelial cells comprising the BBB matrix (Lapchak, Chapman, 
& Zivin, 2000; Mergenthaler, et al., 2004).  Gene knock-out of MMP9 has also been 
shown as a potential treatment for reducing infarct volume (Asahi, et al., 2001).  
Proteolytic damage of the BBB is dangerous for two reasons – first, it causes 
increased invasion and activation of immune cells (as the brain is, in general, a 
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relatively immune-privileged area), and second, because the damage to the matrix 
risks vascular damage, which primes the penumbra for potential hemorrhagic 
transformation. 
 
2.2.4 – Reperfusion Injury 
 One of the major risks associated with thrombolytic treatments (or, in fact, 
non-pharmaceutical removal of arterial blockage) is the risk of a brain hemorrhage 
(Molina, 2006).  As discussed above, an ischemic stroke carries with it the risk of 
vascular weakening.  Once a blockage is removed, the vascular system of the 
penumbra is submitted to a tremendous amount of physical stress as circulation 
returns, carrying with it a potential to rupture blood vessels and induce a secondary 
hemorrhagic stroke (Rosell, Foerch, Murata, & Lo, 2008).  Aside from the risk for 
physical damage, restoration of blood flow to the penumbra can cause complications 
at a cellular level, as the restoration of full metabolic function carries a “heavy cost”, 
involving generation of free radicals, specifically reactive oxygen species (ROS) 
(Chan, 1996; Granger, 1988; Wong & Crack, 2008).  Specifically, the 
overconsumption of ATP during hypoxia results in the accumulation of catabolites 
such as hypoxanthine and xanthine, which, upon re-ignition of cellular metabolism by 
reperfusion, are rapidly metabolised by xanthine oxidase, resulting in a massive spike 
of superoxide and hydrogen peroxide levels (Granger, 1988).  It is important to note 
that the danger in this situation is not simply the accumulation of ROS (which is, after 
all, a standard by-product of cellular metabolism), but also, the rate at which these 
products accumulate during reperfusion.  The  flood of ROS during reperfusion 
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causes damage by overwhelming the cells’ natural ROS mitigation mechanisms 
(enzymes such as superoxide dismutase (SOD), when over-expressed, have been 
shown to reduce final infarct volume in animal models of ischemic stroke (Wong & 
Crack, 2008), an indicator that additional damage handling capability is 
neuroprotective.) 
 In addition to direct oxidative damage, the accumulation of free radicals 
during reperfusion injury is also implicated in the magnification of the inflammatory 
process.  A recent study by Nishi et al. casts some light on the role of oxidative stress 
in modulating immune response (Nishi, Maier, Hayashi, Saito, & Chan, 2005).  In 
brief, they studied the expression of two chemokines using DNA microarray 
technology: MIP-1a and MCP-1, proteins that modulate the function of macrophages 
and monocytes, respectively.  Using a strain of SOD-overexpressing mice, they 
observed changes in MIP-1a and MCP-1 expression in response to the level of 
oxidative stress in the reperfused penumbra.  The results suggested that MCP-1 is 
down-regulated by increased activity of SOD, creating a neuroprotective effect, 
implying that the converse (i.e., increased chemokine activity in response to an 
increase in ROS activity) is a contributor to the inflammatory damage caused by 
reperfusion. 
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3 – The Study of Stroke 
 
 Given the complexities of the pathology of stroke, data obtained from clinical 
patients is limited.  For obvious reasons, histological studies are only possible on 
patients who do not recover from their strokes, and the random nature of the location 
of stroke makes standardisation of observational data, such as that garnered through 
MRI and PET scans, quite difficult.  In response, a number of animal models of 
ischemic stroke have been developed, a brief review of which follows. 
 The first consideration to make when choosing an animal model of stroke is, 
by necessity, which animal to use.  As is the case with all experimental animal 
models, a balance must be struck between physiological similarity to humans and 
ethical and financial considerations.  For this reason, the vast majority of stroke 
studies are performed in rats and mice (Durukan & Tatlisumak, 2007; Gonzalez & 
Kolb, 2003).  The choice of rodent generally depends on the type of study.  Due to 
their ease of handling and care, and their remarkably similar vascular anatomy, most 
physiological and behavioural studies are performed on rats; studies with a genetic 
component are performed on mice.  There are also a small but significant number of 
studies examining higher primates, due to their greater physiological similarity to 
humans (Durukan & Tatlisumak, 2007).  In general, once an experimental technique 
has been demonstrated as effective in a rodent model, it is then ported into a primate 
system before finally being cleared for human study ("Recommendations for 
standards regarding preclinical neuroprotective and restorative drug development," 
1999). 
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 Second, the huge clinical variability of human stroke necessitates a wide 
variety of model systems in order to simulate ischemic events of varying duration 
(from transient models, which feature 60-120 minutes of ischemia and are followed 
by reperfusion, to permanent models, which result in complete devascularisation and 
a permanent ischemic lesion), intensity (from highly localised focal lesions to 
hemispheric disruption), and location (Durukan & Tatlisumak, 2007).  In addition to 
different pathologies, there are also a number of different methods of inducing stroke, 
which, for simplicity’s sake, are divided into two categories, those not requiring 
craniectomy, and those that do. 
 
 3.1 – Experimental Models of Stroke 
 3.1.1 – Methods not Requiring Craniectomy 
 The first of these methods, induced thromboembolism, is also one of the 
oldest, and seeks to mimic the cause of a vast majority of human strokes (Durukan & 
Tatlisumak, 2007).  This method of stroke induction uses either fragments of a pre-
existing autologous thrombus (Kaneko, Nakamura, & Ogawa, 1985), or fragments of 
a human blood clot (S. M. Papadopoulos, Chandler, Salamat, Topol, & Sackellares, 
1987) to induce clotting activity in the cerebral arteries of the experimental subject.  
Generally, the ‘seed thrombus’ is injected into the carotid artery.  It will stimulate the 
development of clotting at a downstream point, or simply physically block an artery.  
One of the major advantages of this method is its similarity to the pathology of a 
human embolic stroke – its source is in fact a blood clot.  This is especially useful for 
examining the effects of thrombolytic and neuroprotective drugs, but can be 
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problematic due to lack of experimenter control.  As the seed thrombus is injected 
into a major artery, it is very difficult to control the final location of the induced 
stroke (rendering it a suboptimal method for behavioural studies).  In addition, clots 
of this nature are unpredictably vulnerable to spontaneous autolysis, making the 
duration of ischemia difficult to control (rendering the standardization of data across 
multiple animals difficult).  Though some of these difficulties are controllable using 
artificial means to induce an embolism (see (Durukan & Tatlisumak, 2007; Gonzalez 
& Kolb, 2003) for review), the resultant thrombus is still vulnerable to any number of 
factors that vary from individual to individual. 
 In an attempt to maintain an accurate simulation of arterial blockage as the 
source of neural ischemia, but obtain greater control of the duration and localization 
of the resulting infarct, a number of non-thrombic methods of inducing arterial 
blockage have been developed.  The most commonly used of these (and, in fact, the 
most common stroke model), is occlusion of the middle cerebral artery (MCAO) 
(Yanamoto, et al., 2003).  Using a minimally-invasive surgical technique, a small 
suture is inserted into the carotid artery, and can simply be advanced to the point 
where it blocks the middle cerebral artery, resulting in ischemia at all points 
downstream.  Once the desired ischemic duration has been reached, the suture can be 
simply withdrawn from the carotid, allowing for reperfusion of the affected tissue.  A 
variety of techniques have been used to modulate the pathology of MCAO, including 
alterations of suture diameter (Yanamoto, et al., 2003), and the chemical composition 
of the sutures themselves (Laing, Jakubowski, & Laing, 1993).  The major 
disadvantages of this method are the potential for mechanical damage of the artery, 
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resulting in subarachnoid hemorrhage, and induction of systemic hyperthermia 
(Durukan & Tatlisumak, 2007; F. Li, Omae, & Fisher, 1999).  Furthermore, though 
some selectivity of localization is possible, MCAO still results in very large 
infarctions, which renders the technique suboptimal for the study of focal ischemia. 
 A notable craniectomy-less model of stroke involves injection of endothelin-1, 
a potent vasoconstrictor, into the MCA (Robinson, Macrae, Todd, Reid, & 
McCulloch, 1990).  This avoids many issues present in MCAO-type methods, as the 
surgical invasiveness is limited to a relatively simple injection.  Another major 
advantage of endothelin-1 is that it can be injected directly onto the cortex in order to 
generate focal lesions (Fuxe, et al., 1997), which allows for the study of stroke in 
specific brain areas.  This is particularly useful when studying behaviour, and 
behavioural recovery.  Disadvantages of this method include the dose-dependent 
response of vasoconstriction to the injection, and the fact that the injected endothelin-
1 is exhausted and metabolised, which limits the effectiveness of this method for 
inducing strokes of a controlled duration (Durukan & Tatlisumak, 2007).  Also of 
note is the increased invasiveness of this method when used to generate focal lesions, 
as it requires direct surgical access to the cortex. 
Another experimental model for localised stroke induction, photothrombosis, 
involves injection of a photoreactive dye into the bloodstream, and its subsequent 
activation by a laser set to a specific frequency (Watson, Dietrich, Busto, Wachtel, & 
Ginsberg, 1985).  The active form of the dye generates singlet oxygen, causing 
endothelial damage and platelet activation, triggering an intense focal ischemia.  This 
photochemical method allows the experimental induction of identical lesions in 
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multiple animals, but due to the intensity of the lesion generated, creates nearly no 
penumbra (as any area targeted by the laser experiences full oxygen deprivation and 
complete necrosis within minutes).  Though manipulation of the intensity and 
duration of the laser burst has been shown to alter the physiology of the lesion 
(Durukan & Tatlisumak, 2007), the study of the penumbra (and specifically any drug 
therapies that target it) is best done in other models. 
 
3.1.2 – Methods involving Craniectomy 
 Craniectomy-type model systems involve opening the skull of the animal and 
using a variety of means, physical or chemical, to induce vascular damage in selected 
brain regions.  Though the main disadvantage of these methods, namely the 
complications associated with general anaesthesia and open-brain surgery, is 
significant, these methods allow a great deal of experimenter control in terms of the 
location, extent, and duration of ischemia.  Two main subcategories of surgical stroke 
models exist – surgical occlusion of the cerebral arteries, and direct interference with 
the neurovascular system (Durukan & Tatlisumak, 2007).  Surgical occlusion of the 
MCA is the most common model of this type.  MCA occlusion is accomplished either 
by physical obstruction of the vessel (using either ligatures, micro-clamps or suturing 
(Buchan, Xue, & Slivka, 1992; Shigeno, Teasdale, McCulloch, & Graham, 1985)) or 
electrocauterization (Hellstrom, Wanhainen, Valtysson, Persson, & Hillered, 1994), 
the former of which allows for reversal of ischemia and the study of reperfusion.  The 
extent of the lesion is dependent on the location of MCA occlusion (Tamura, Graham, 
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McCulloch, & Teasdale, 1981), as discussed above.  This allows surgical MCAO to 
be quite precise in the generation of lesions. 
 One final method of note is devascularisation of the motor cortex.  Though 
this method involves craniotomy, and the resultant dangers of atmospheric exposure 
and potential disruption of the blood-brain barrier, it is extremely reliable as a model 
for permanent focal ischemia.  Physical ablation of the pia matter results in permanent 
devascularisation of the cortex, causing both a large ischemic core, as well as a 
consistent penumbra surrounding this core.  Furthermore, a detailed comparison of 
multiple stroke methods (Gonzalez & Kolb, 2003) reveals that the devascularisation 
method generates increased dendritic plasticity when compared to MCAO.  Though 
the causes of this differing morphological aetiology are yet to be determined, this 
finding suggests that the method of stroke induction plays a major role in the brain’s 
response to injury.   
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4 – Post-Stroke Gene Expression and Neural Plasticity 
 
Following a stroke to the motor cortex, the brain undergoes a series of plastic 
responses in an attempt to recover from the resultant damage.  These plastic responses 
include axonal sprouting and synaptic plasticity (Carmichael, 2006), as well as a 
limited degree of neurogenesis (Jin, et al., 2001) and migration of neural progenitors 
to the peri-infarct region (Kokaia, Thored, Arvidsson, & Lindvall, 2006).  This 
enhanced plasticity allows the brain to re-arrange the sensorimotor maps of the 
damaged area and compensate, to a degree, for the function lost during the stroke 
(Carmichael, 2006).  It has long been known that neural plasticity is a direct result of 
changes in the protein complement of a neuron (Sutton & Schuman, 2006), and that 
this change is driven by altered gene expression in response to synaptic activity 
(Cavallaro, Schreurs, Zhao, D'Agata, & Alkon, 2001).  Recent evidence suggests that 
these altered levels of gene expression are under the control of at least two epigenetic 
mechanisms; DNA methylation and histone acetylation (Miller, Campbell, & Sweatt, 
2008).   
  
4.1 - Epigenetics 
Epigenetic changes, sequence independent heritable alterations in gene 
expression, include three major processes (Egger, Liang, Aparicio, & Jones, 2004).  
The first of these involves methylation of DNA, most commonly at cytosine residues.  
Addition of methyl groups to carbon 5 of cytosine in DNA acts as a direct blocker of 
transcription, which leads directly to the silencing of the methylated regions.  The 
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second process, histone modification, is directed at controlling the structural 
organisation of DNA.  Histones, small nuclear proteins which use their predominantly 
positively charged functional groups to bind and ‘wrap up’ the negatively charged 
DNA molecule, are the target of numerous modification enzymes.  These enzymes 
can attach and remove functional groups in order to change the fundamental chemical 
properties of histones, and, correspondingly, their ability to bind DNA.  The more 
tightly the histone binds the DNA, the lower the expression of the genes contained in 
this region.  The third and most recently discovered process, non-coding RNA 
interaction, will be covered in greater detail in section 4.2.  Cells are capable of 
regulating their translational activity by the use of small RNA molecules, which are 
capable of binding mRNA transcripts and influencing their activity downstream of 
their exit from the nucleus.  RNA epigenetic regulation operates as a second level of 
control – DNA methylation and histone modification both can directly affect the 
amount of mRNA produced, while non-coding RNA controls what happens to the 
mRNA after it is produced (Fabbri, Ivan, Cimmino, Negrini, & Calin, 2007).   
Interestingly, recent evidence suggests that all three of these processes are 
capable of directing each other’s activity (Egger, et al., 2004).  It also appears that 
these processes operate most often to silence, rather than activate, genes.  Considering 
that each cell must specialise with respect to function, though it contains all of the 
sequence information necessary to form an entire organism, this is not surprising.  
Epigenetic regulation is more accurately defined as the interplay of multiple 
independent regulators of gene silencing, to specialise and differentiate cells into 
specific phenotypes. 
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4.1.1 – DNA Methylation 
 Cytosine DNA methylation was the first identified epigenetic regulation 
mechanism, and has thus been the most closely studied.  It is a crucial mechanism for 
normal cellular function, and has been shown to play a major functional role in 
development, cell proliferation, and maintenance of genome stability (Baylin, 2005; 
Baylin & Ohm, 2006; Jaenisch & Bird, 2003).  Most DNA methylation occurs at CpG 
dinucleotides, which consist of a C next to a G in the nucleotide sequence, causing 
the complimentary strand to consist of a G next to a C.  60-80% of CpG dinucleotides 
are methylated (Weber & Schubeler, 2007).  A large majority of genes contain CpG 
islands in their promoter regions, and are therefore sensitive to methylation changes. 
The symmetry of these CpGs is crucial in the maintenance of methylation patterns 
through multiple generations of cells, as explained below.  Healthy cells have 
relatively unmethylated CpG islands in front of their active genes, while silent genes, 
repetitive sequences and transposons are heavily methylated (Luczak & Jagodzinski, 
2006).   
The activity of a region of DNA depends directly on the ability of DNA-
binding proteins, such as transcription factors and polymerases, to bind to it.  DNA 
binding domains are capable of detecting variations in sequence which are 
responsible for the specificity of their parent proteins by interacting with the major 
groove of the DNA (Wolfe, Nekludova, & Pabo, 2000).  Once a transcription factor 
binds its target DNA sequence, it is capable of initiating assembly of the RNA 
polymerase holoenzyme, causing gene products downstream of the promoter to be 
transcribed.  However, should the major groove of DNA become cluttered and 
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spatially inaccessible, both transcription factors and polymerases have difficulty 
binding the DNA and performing their required tasks of initiation and elongation, 
respectively.  Addition of a methyl group to the 5’ carbon on the cytosine molecule 
results in a protrusion of this methyl group into the major groove of the DNA 
molecule (Newell-Price, Clark, & King, 2000).  Should a region of DNA become 
heavily methylated in this manner, these methyl groups will significantly block access 
to the sequence, resulting in a silent gene (Weber & Schubeler, 2007).   
The second major factor whereby CpG methylation is responsible for 
downregulation of gene expression is due to the behaviours of the methyl CpG 
binding domain (MBD) family of proteins (Klose & Bird, 2006).  These proteins, 
including MeCP2, MBD1, MBD2, and MBD3, selectively interact with methylated 
DNA and play a pivotal role in methylation-mediated chromatin remodelling and 
gene silencing (Jaenisch & Bird, 2003; Newell-Price, et al., 2000; Robertson, 2002).  
For a description of chromatin remodelling through histone alterations, see section 
4.1.2. 
Methylation takes place through the activity of enzymes known as DNA 
methyltransferases, enzymes capable of covalently adding methyl groups to 
unmethylated DNA bases (Robertson, 2005).  It can be subdivided into two 
categories; de novo methylation, which describes the addition of novel methyl groups 
to unmethylated DNA, and maintenance methylation, which adds methyl groups to 
hemimethylated DNA during replication.  In mammals, three DNA 
methyltransferases are primarily responsible for establishing and maintaining CpG 
methylation patterns, with DNMT1 being the primary maintenance methyltransferase 
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and DNMT3a and DNMT3b in charge of de novo methylation (Goll & Bestor, 2005).  
When DNA is replicated, the parental strand maintains its methylation pattern, which 
is read by DNMT1 due to its localisation at the replication fork.  If a methyl-CpG is 
detected, DNMT1 will add a methyl group to its symmetrical complimentary CpG 
(Goll & Bestor, 2005; Weber & Schubeler, 2007).  Due to this symmetry, the 
methylation pattern can be maintained in both copies of the new DNA.  The de novo 
methyltransferases, on the other hand, are capable of modifying unmethylated CpG 
pairs and are important in tissue differentiation as well as the establishment of new 
hypermethylated CpG islands in cancer (Esteller, 2007).  This seems, at first, 
paradoxical, since cancer’s primary phenotype is that of a loss of differentiation, 
which is brought about by methylation.   An explanation of this paradox, as well as its 
clinical implications, will be covered below. 
 
4.1.2 – Histone Modification 
 A second level of epigenetic regulation is provided by alteration of the histone 
proteins, which regulate the packaging and organisation of the DNA.  Through the 
action of the histone proteins, a single linear strand of DNA can be condensed into the 
highly structured mitotic chromosome.  Histones show high affinity to DNA since 
they are positively charged, while DNA is negatively charged.  Post-translational 
modifications of histones are capable of altering both their charge, and their 
capability for non-electrostatic intramolecular interaction, and therefore their affinity 
for DNA, which has an impact on the transcriptional activity of the DNA.  If DNA is 
tightly wrapped around a histone, it becomes more difficult for transcription factors to 
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access it, which, as discussed above, results in a net decrease in the activity of the 
gene involved.  Histone modification is unique among the epigenetic regulatory 
mechanisms, as it is the only modification capable of actually amplifying the activity 
of a specific region of DNA, since modifications to histones can either increase or 
decrease their net positive charge (Jenuwein & Allis, 2001).  This variability of 
histone/DNA interaction is reflected in the large number of possible modifications to 
histones, including acetylation, phosphorylation, methylation, ubiquitination, and 
their inverse processes (Reamon-Buettner & Borlak, 2007).  Discussion of every form 
of histone modification is outside the scope of this work, but the major subtypes of 
histone modification, methylation, acetylation and their inverse processes bear 
examination. 
 Subunit H3 and H4 contain several highly conserved lysine residues at their 
N-terminal tails.  These specific residues are the primary targets of the acetylation 
mechanism, which uses enzymes known as HATs (histone acetyltransferases) to 
catalyse the transfer of an acetyl group from acetyl coenzyme A to the histone lysine 
(Nakao, 2001).  Addition of the negatively charged acetyl group reduces the positive 
charge of the histone, and consequently reduces its affinity to DNA.  This relatively 
loosely wound and transcriptionally active DNA is known as euchromatin.  
Deacetylation, the reverse process, is carried out by HDACs (histone deacetylases), 
which transfer acetyl groups by hydrolysing NAD to produce acetyl-ADP-ribose 
(North & Verdin, 2004).  Due to the relative ease with which it can open and close 
the chromatin, histone acetylation is a very attractive target for further studies of 
pharmacological intervention.  Methylation of lysine 9 of histone H3 is associated 
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with chromatin compaction and gene silencing, while methylation of lysines 4 and 27 
of histone H3 results in transcription activation and chromatin relaxation. 
Additionally, histone residues can be mono-, di- and tri-methylated, which results in 
an enormously complicated histone code (Cheung & Lau, 2005; Weidman, Dolinoy, 
Murphy, & Jirtle, 2007).  In addition, DNA methylation and histone modification 
have been shown to be causally linked through the activity of methyl-CpG binding 
proteins such as MeCP2 (Jones, et al., 1998).   
 
4.2 – Short RNA Epigenetic Modulation 
The role of the third major type of epigenetic regulation is short RNA 
mediated alterations of translation.  The role that this form of regulation plays in 
neural plasticity has not been fully explored.  One of the main goals of the current 
study was to examine the roles that micro-RNA, an endogenously expressed form of 
short RNA responsible for the suppression of translation in mammalian cells, may 
play in the plasticity that accompanies stroke recovery. 
 
 4.2.1 – A brief History of microRNA  
 In 1993, Rosalind Lee, Rhonda Feinbaum and Victor Ambros discovered a 
strange gene in C. elegans that would create an entire field of study, and trigger the 
exploration of a new field of novel epigenetic regulation.  The lin-4 gene, known to 
regulate the timing of developmental events in the worm, was found to produce two 
RNA molecules, but no subsequent protein products (R. C. Lee, Feinbaum, & 
Ambros, 1993).  One of these products, 61nt in length, was predicted to be a stem-
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loop precursor molecule for the other, which was 21nt in length (R. C. Lee, et al., 
1993; Wightman, Ha, & Ruvkun, 1993).  Intriguingly, the 21nt molecule was found 
to have anti-sense complimentarity to the 3’ untranslated region (3’UTR) of a gene 
known as lin-14, which had been previously shown to be regulated by the lin-4 gene 
product through an unknown form of 3’UTR interaction (Wightman, Burglin, Gatto, 
Arasu, & Ruvkun, 1991).  The study also showed that lin-4 mediated regulation of 
lin-14 reduced the circulating levels of lin-14 protein, but not its corresponding 
mRNA (R. C. Lee, et al., 1993).  These studies, taken together, suggested that the 
short RNA product of lin-4 bound the 3’UTR of lin-14 and prevented the production 
of its protein. 
 These discoveries were initially described as an oddity of the worm genome, 
and left unexplored until the discovery of another regulatory short RNA in C. 
elegans, let-7 (Reinhart, et al., 2000).  Unlike lin-4, let-7 is a highly conserved gene 
in multiple phylogenies, and shows a similar expression and regulatory pattern across 
all of them (Pasquinelli, et al., 2000).  Shortly thereafter, a large number of let-7 like 
gene products were discovered, and the entire class of molecules were named 
microRNA (miRNA). These molecules have since been implicated in a multitude of 
cellular processes, including development, proliferation, differentiation, neuronal 
patterning, and carcinogenesis (D. P. Bartel, 2004; B. Zhang, Wang, & Pan, 2007).  
Since this revelation, there have been literally hundreds of miRNAs identified and 
isolated in numerous species, including nearly 700 identified in humans as of early 
2009 (G. L. Papadopoulos, Reczko, Simossis, Sethupathy, & Hatzigeorgiou, 2009), 
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with the latest computational models predicting roughly 1000 human miRNAs in total 
(Berezikov, et al., 2005).   
 
4.2.2 – MicroRNA Genomics 
 The majority of miRNAs are transcribed from genomic regions quite distant 
from other annotated gene products (Lau, Lim, Weinstein, & Bartel, 2001), indicating 
that they exist as independent transcription units (Berezikov, et al., 2005; Ying & Lin, 
2009).  A significant minority of miRNAs, however, are located within the introns of 
other genes (D. P. Bartel, 2004; Ying & Lin, 2009), and though they share a similar 
method of action as independent miRNA genes, their biogenesis is different, as it 
involves components of the spliceosome (Ying & Lin, 2009).  This has lead to some 
degree of speculation that intronic miRNA and independent miRNA may have 
slightly different regulatory roles (Lin, Miller, & Ying, 2006).  The genomic 
arrangement of miRNA varies, with a number of independent miRNA genes being 
located in two different types of clusters, either based on sequence homology (Lagos-
Quintana, Rauhut, Lendeckel, & Tuschl, 2001) or product function (Lau, et al., 2001).  
Intronic miRNAs, of course, are clustered with the products of the genes from which 
they are produced, leading to the speculation that such protein-miRNA pairings form 
the basis of regulatory mechanisms (D. P. Bartel, 2004).  A number of miRNAs are 
also associated with other prominent gene clusters, notably the Hox gene cluster 
(Aravin, et al., 2003; Lagos-Quintana, Rauhut, Meyer, Borkhardt, & Tuschl, 2003), 
suggesting that co-regulation of miRNA and protein expression plays a major role in 
the developmental process. 
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4.2.3 – miRNA Biogenesis 
 miRNAs go through a complex process to progress from their genomic form 
to their active cytoplasmic form (Figure 1).  Independent miRNA genes are generally 
transcribed by Pol II (Esquela-Kerscher & Slack, 2006; Lau, et al., 2001), resulting in 
a primary transcript of varying length (depending on the structure of the miRNA gene 
– polycistronic miRNAs can have a primary transcript kilobases long (D. P. Bartel, 
2004)).  There is additional evidence suggesting that some miRNA genes are also 
transcribed by Pol III, as an artificial miRNA construct driven by the Pol III promoter 
can produce functional mature miRNAs (C. Z. Chen, Li, Lodish, & Bartel, 2004).  
Intronic miRNA is likewise transcribed by Pol II, as a consequence of the 
transcription of its home gene.  Once the gene is fully transcribed, the spliceosome 
excises the introns from the primary transcript (Lin, et al., 2006; Ying & Lin, 2009).  
The major differences between the two types of primary transcript are the presence of 
a 5’ cap and a polyA tail in the independently expressed miRNA genes, and the lack 
thereof in intronic miRNA. Following transcription, the primary transcript, known as 
the pri-miR is processed by an RNAse III enzyme Drosha, and a dsRNA binding 
protein Pasha (DCGR8) (Esquela-Kerscher & Slack, 2006).  The Drosha enzyme cuts 
the flanking sequences away from the base of the 70-80nt stem-loop structure (Y. 
Lee, et al., 2003), resulting in a pre-miR (the 61nt structure found in the original 1993 
study (R. C. Lee, et al., 1993)).  Drosha cuts the pre-miR leaving a characteristic 
pattern, a 5’ phosphate and a 2nt long 3’ overhang (Y. Lee, et al., 2003), a pattern that 
may play a major role in the later maturation of the miRNA sequence by determining 
which strand will be processed as a mature miRNA (D. P. Bartel, 2004).  Pre-miRs 
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are subsequently exported from the nucleus by a complex of Exportin-5 and RAN-
GTP (Bohnsack, Czaplinski, & Gorlich, 2004; Yi, Qin, Macara, & Cullen, 2003), and 
undergo another processing step in which the active miRNA (bound to its 
complimentary strand, known as the miRNA:miRNA* duplex (D. P. Bartel, 2004)) is 
excised from the pre-miR by the Dicer RNAse III enzyme (Ketting, et al., 2001).  
Dicer was previously known as the RNAse responsible for the generation of short 
interfering RNA (siRNA), and appears to mediate the cleavage of pre-miRs in a 
similar fashion (Bernstein, Caudy, Hammond, & Hannon, 2001).  Dicer cleaves the 
loop from a pre-miR, producing a 19-22nt long dsRNA miRNA:miRNA* structure. 
 From this point, the biological activity of miRNA mimics the pathways 
already identified in RNA interference, where short dsRNA sequences are used to 
target post-transcriptional gene silencing (PTGS) (D. P. Bartel, 2004).  In RNAi, long 
cytoplasmic dsRNAs are also processed by Dicer, which cleaves them into 19-22nt 
long fragments.  Though the exact process remains unclear, what is known is that 
these 19-22nt fragments are loaded onto a member of the Argonaute family, 
processed, and eventually incorporated into a ribonucleoprotein complex known as 
the RNA-induced silencing complex (RISC) as single-stranded RNA molecules, 
known as guide strands.  The choice of the guide strand is currently thought to be 
determined by the differences in thermodynamic stability of the 5’ ends of the two 
strands of the dsRNA duplex (Siomi & Siomi, 2009), causing the strand whose 5’ end 
is located at the less stable end of the duplex to be chosen as the guide strand 
(Schwarz, et al., 2003).  Though the enzyme responsible for the selection and 
unwinding of the guide strand remains unidentified, this asymmetry rule, coupled 
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with the eventual discarding of the miRNA*, has led to speculation that a helicase-
type enzyme (given the temporary name unwindase) samples each end of the duplex 
multiple times, probing its thermodynamic stability, and then fully unwinds the 
duplex and removes the unused complimentary strand.  Assembly of the RISC 
proceeds either subsequently to or simultaneously with the processing of the guide 
strand, though currently its exact constituent members are not yet known (and, in fact, 
are thought to vary, forming several different subtypes of RISC (D. P. Bartel, 2004)).  
Despite this, a number of common constituent members have been identified, 
including multiple members of the argonaute family (AGO1, AGO2), fragile X 
proteins (FRAX) (Soifer, Rossi, & Saetrom, 2007), p54 (Esquela-Kerscher & Slack, 
2006), and Tudor-SN (van den Berg, Mols, & Han, 2008).  
Once assembled, the RISC uses the guide strand to scan the transcriptome and 
induce post-transcriptional silencing by one of two methods, mRNA cleavage or 
translational repression (D. P. Bartel, 2004).  It has recently been determined that 
Ago2 is the nuclease responsible for RISC-mediated cleavage of mRNAs (van den 
Berg, et al., 2008).  The decision to cleave or not to cleave is not determined by the 
source of the short RNA in the RISC.  Instead, the complex initiates cleavage if there 
is sufficient homology between the guide strand and the targeted mRNA.  This 
cleavage occurs in the mRNA location corresponding to nucleotides 10 and 11 of the 
guide strand, in both mi-and-siRNA directed cleavage (Elbashir, Lendeckel, & 
Tuschl, 2001; Hutvagner & Zamore, 2002).  Following Ago2 mediated cleavage, the 
RISC un-docks from the target mRNA, and can use the same guide strand to locate 
new mRNA targets. 
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Should the guide strand lack sufficient complimentarity to an mRNA target, 
the RISC induces translational silencing instead of direct mRNA cleavage.  The 
mechanism of translational repression has been most closely studied in C. elegans lin-
4, where a number of possibilities have been proposed.  First, the complex of the 3’ 
end of the mRNA containing the RISC may coil around and physically interfere with 
ribosomes, stalling them on the transcript.  Alternately, the action of the RISC may in 
fact target newly synthesised polypeptides for degradation, though this seems less 
likely as a mechanism (D. P. Bartel, 2004).  A more recent study suggests that the 
RISC physically interfaces with the 5’ cap of the mRNA, preventing ribosomes from 
loading (Pillai, et al., 2005).  This was demonstrated by the fact that M7G-cap-
independent translation of a luciferase reporter construct was not suppressed by let-7 
activity.  There is still some controversy regarding the mechanism of RISC-mediated 
translational suppression, giving rise to the need for further study of the biochemistry 
and stoichiometry of RISC assembly and behaviour (van den Berg, et al., 2008). 
Once translation has been suppressed, the question arises as to the fate of the 
suppressed mRNA.  The first insight into this was the co-localization of 
translationally repressed mRNAs and a de-capping protein DcP1a (Pillai, et al., 
2005).  The Pillai group postulated the existence of cytoplasmic foci, termed p-
bodies, which contained the apparatus for degradation of suppressed mRNA, a 
hypothesis which was further strengthened by the subsequent discovery of Ago2 co-
localization to the same foci (Sen & Blau, 2005).  The final piece of the puzzle came 
in the same year, showing that active miRNAs likewise translocate to the same area 
(Liu, Valencia-Sanchez, Hannon, & Parker, 2005).  Inside these p-bodies, mRNAs 
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are simultaneously uncapped and digested, which frees the components of the RISC 
to resume scanning the transcriptome (van den Berg, et al., 2008).   
 
 4.2.4 – Target Recognition 
 The difficulty in predicting the behaviour of miRNAs lies in their capability of 
acting through imperfect complimentarity.  Unlike siRNAs and plant miRNAs, which 
generally induce mRNA cleavage due to perfect guide strand / target strand 
complimentarity, the vast majority of animal miRNA regulation appears to utilize the 
translational repression pathway (B. Bartel & Bartel, 2003; D. P. Bartel, 2009).  This 
has led to a variety of computational and experimental methods attempting to 
determine the nature of miRNA – mRNA targeting.  Historically, the first iteration of 
miRNA target prediction was based primarily on the degree of complimentarity 
(Lewis, Shih, Jones-Rhoades, Bartel, & Burge, 2003), a method which generated a 
high number of false positives.  Fortunately, due to recent biochemical and 
bioinformatic analyses, it was determined that the complimentarity of the 5’ end of 
the miRNA is a ‘seed sequence’ (Doench & Sharp, 2004; Parker, Roe, & Barford, 
2006).  In order for miRNA targeting to occur effectively, nucleotides 2-7 of the 5’ 
end of the guide strand must demonstrate perfect or near-perfect complimentarity to 
the target sequence in the mRNA 3’UTR (Smalheiser & Torvik, 2006).  Inclusion of a 
strict “seed sequence” principle greatly reduced the amount of false positives 
produced by computational models (D. P. Bartel, 2009).  Interestingly, a great deal of 
miRNA activity can be predicted simply by seed sequence alignment (Lewis, Burge, 
& Bartel, 2005).  These models have also begun to take into account conservation of 
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sequences as a predictive tool.  Given that miRNA regulation appears  to be a major 
regulatory pathway, it can be postulated that miRNA/mRNA targeting is under some 
degree of selective pressure.  Since mature miRNA sequences have been shown to be 
conserved across multiple phyla, one can safely assume that the target sequences are 
likewise conserved.  By increasing the stringency of cross-species comparisons, 
modern computational models are rapidly increasing in accuracy and reliability for 
the prediction of miRNA targeting (D. P. Bartel, 2009). 
 In light of the available data, roughly six flavours of miRNA target pairing 
have been identified.  The 7mer-A1 site possesses a perfect seed match at positions 2-
7, and an adenine at residue 1, and represents the standard model for seed sequence 
binding.  Variants of this binding pattern, such as the 7mer-m8 site (lacking the 
adenine, but possessing an additional base pair at nt8) and the 8-mer site (adenine at 
position 1, perfect match from 2-8), are also quite common.  These three sites account 
for roughly 60% of all predicted miR-target interaction in humans (D. P. Bartel, 2009; 
Friedman, Farh, Burge, & Bartel, 2009).  The remaining 40%, known as atypical 
binding sites, are comprised of 6-mer (adenine at position 1, seed match from 2-6) 
and offset 6-mer sites (no adenine, seed match from 3-8).  These marginal sites 
typically show reduced miRNA efficacy (D. P. Bartel, 2009).  A final type of target 
pairing is very rare, and consists of a mismatch in the seed region, which is 
compensated for by additional base pairing in the 3’ region of the miRNA, a targeting 
method that again shows reduced efficacy when compared to the canonical sites.  In 
addition to any of the above seed region pairings, many miRNAs also possess 
supplementary 3’ complimentarity sites, which were thought to enhance miRNA 
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action.  This may or may not be the case, as there is currently a lack of experimental 
support for frequent 3’ supplementary action (D. P. Bartel, 2009; Brennecke, Stark, 
Russell, & Cohen, 2005; Doench & Sharp, 2004), and furthermore, all of the 
energetic models developed to describe this action lack predictive power (Baek, et al., 
2008; D. P. Bartel, 2009). 
 The initial hypothesis regarding the importance of supplementary 3’ pairing 
was developed owing to an effect that is quite common in molecular biology research 
– the initial discovery drives the tone of future research.  The binding of let-7 to lin-
41 in C. elegans is dependent on supplementary 3’ interaction (Vella, Choi, Lin, 
Reinert, & Slack, 2004), which led researchers to believe that this type of binding 
exemplified miRNA-target interaction (Vella, Reinert, & Slack, 2004).  The relative 
rarity of this type of binding (1% of all predicted interaction (D. P. Bartel, 2009)) was 
only determined at a later date (Friedman, et al., 2009), which then led to further 
evolution of algorithms for target prediction.  The relatively low frequency of 3’ 
supplementary sites in the genome may be due to the increased informational 
complexity of the system, which is far more difficult to conserve in an evolutionary 
sense (D. P. Bartel, 2009). 
 If miRNA binding appears to be almost solely dependent on the sequence of 
the seed region, what, then, is the purpose of the other 11-13 nucleotides of the miR, 
and how does the physical arrangement of the miRNA in the RISC contribute to its 
function?  One possible model (D. P. Bartel, 2004; Mallory, et al., 2004) suggests that 
the seed region of the miRNA is loaded into the Argonaute protein, and arranged into 
an A-form helix from nucleotides 2-7, which enhances both the specificity and 
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affinity of Watson-Crick base pairing in the seed region. This avoids the spatial 
interference that would arise from arranging the entire miRNA in a helical formation 
(D. P. Bartel, 2009).  The increased affinity for the seed region predicted by this 
model was shown in two recent studies (Ameres, Martinez, & Schroeder, 2007; Haley 
& Zamore, 2004), both of which demonstrate a significant increase in hybridization 
kinetics if the RISC becomes involved.  This suggests that miR-target interaction is 
catalysed by the above conformational changes induced in the miRNA by Ago.  
 Regarding the behaviours of the distal 3’ end of the miRNA, a model has been 
proposed by a number of researchers, termed the ‘seed-nucleation’ model.  Based on 
evidence from a number of earlier studies (Ameres, et al., 2007; D. P. Bartel, 2004; 
Haley & Zamore, 2004; Mallory, et al., 2004), this model proposes a two-stage 
process whereby the seed region, first, pairs to the target strand , associating the it 
with the RISC, and second,  induces the 3’ tail of the miRNA to coil around the 
remainder of the mRNA using base pairing rules, creating the dsRNA structure that 
Ago2 is capable of cleaving (in the case of perfect complimentarity).  It is postulated 
that the association between the 3’ end of the miRNA and the Ago protein protects it 
from degradation from cytoplasmic RNAses.  This would necessitate the release of 
the miRNA from the Ago protein in order to allow it to bind the target strand.  Bartel 
suggests that beginning at the seed region, successive base pairing induces sequential 
release of the miRNA nucleotides from the Ago protein, allowing the miRNA to 
slowly bind the target strand in a helical formation (D. P. Bartel, 2009).  This model 
would also account for the apparent lack of kinetic advantage provided by 3’ miRNA 
binding, as the energy gains from the bonding of the central nucleotides would be 
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offset by the energy losses caused by the disengagement of the miRNA from Ago and 
its resultant conformational changes. 
 
4.2.5 – Analysis of miRNA Expression 
 With over 1000 miRNAs active in humans, it is necessary, and relevant, to 
analyse the behaviour of the entire miRNAome, as well as the interactions between 
miRs and their targets (given that one miRNA can have multiple targets, and one 
gene can be targeted by multiple miRs (D. P. Bartel, 2004)).  A number of techniques 
have been adapted to the miRNA field to accomplish this, including Northern 
blotting, reverse transcriptase polymerase chain reaction (RT-PCR), miRNA 
microarrays, and ISH (W. Li & Ruan, 2009).   
Northern blot consists of the separation of miRNAs from total cellular RNA 
by polyacrylamide gel electrophoresis, transfer of this RNA to a membrane, and 
qualitative and quantitative detection of a target sequence by hybridization of 
radiolabelled probes.  This technique is useful, as it can be used to measure the 
expression level of several miRNAs relatively inexpensively (Sempere et al, in a 
recent study, examined the expression levels of 119 different miRNAs in various 
mouse tissues (Sempere, et al., 2004)), though the portion of total cellular RNA 
comprised of miRNA is quite low.  Several protocols have been developed to increase 
the affinity of probes to miRNA and increase the signal-to-noise ratio of Northern 
detection of miRNA, including the use of locked nucleic acid (LNA) probes (W. Li & 
Ruan, 2009), which are synthetic oligonucleotides that show enhanced affinity to 
RNA. 
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 Another method in common use, RT-PCR, makes use of reverse transcriptase 
and the polymerase chain reaction to amplify and quantify specific RNA sequences of 
interest.  A major difficulty of this method is the similarity in size between traditional 
PCR probes and mature miRNA sequences (W. Li & Ruan, 2009).  This problem has 
been overcome by the development of stem-loop primers (C. Chen, et al., 2005) 
which bind the miRNA, and  subsequently, can be extended by the PCR reaction.  
They amplify themselves, and their relative levels of amplification after a given 
number of PCR cycles can be used to quantify the original levels of miRNA.  Stem-
loop primers have  such high specificity and efficiency that they can be used to detect 
miRNAs arising from a single cell (C. Chen, et al., 2005). 
 The third major method for miRNA analysis, in-situ hybridization, permits  
spatial distribution of miRNAs in microscopic preparations to be visualized (W. Li & 
Ruan, 2009).  This is especially useful for the examination of roles that the miRNA 
may play in heterogeneous tissues (for example, the activity of a given miRNA in a 
neuron may have a vastly different etiological consequence than the activity of that 
same miRNA in a glial cell).  ISH suffers from much the same problem as Northern 
blotting, due to the relatively low affinity between standard probes and short RNAs.  
This issue has been addressed by  adaptation of LNA probe technology to the method, 
allowing for very precise detection of miRNA distribution (Wienholds, et al., 2005). 
 Perhaps one of the most powerful tools for analysis of miRNA expression at 
the level of the miRNAome is the microarray.  This method, though it lacks the  
reputation of Northern blotting, the extreme sensitivity of RT-PCR,  and the spatial 
sensitivity of ISH, combines extremely high throughput and rapid data analysis, while 
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still maintaining excellent levels of quantitative sensitivity (W. Li & Ruan, 2009).  
Microarrays function on the principle of nucleic acid hybridization between target 
molecules and corresponding complementary probes.  These probes, designed in 
advance from sequence databases, in this case, corresponding to the mature sequence 
of miRNAs, are cross-linked onto glass slides, forming the array.  Isolated samples 
are then treated with a fluorescent dye, and hybridized to the array, with the miRNAs 
of interest binding specifically to their complimentary probes.  Luminescent analysis 
of the array indicates the presence or absence of a particular anti-probe in a given 
sample, as well as an estimation of the relative quantity of any given miRNA, as more 
abundant miRNAs will generate a greater fluorescent signal as they concentrate on 
the probe.  Statistical analysis of two different samples applied to duplicate arrays 
allows for a side-by-side comparison of the miRNAomes of two different conditions, 
indicating increased or decreased expression levels of miRNAs of interest. 
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5 – Statement of Purpose 
 This study aims to examine the role that microRNA plays in the progression 
of stroke recovery, at a distal time point (4 months post-lesion).  Given the high 
degree of plasticity exhibited by recovering brains, and the necessity for tightly-
regulated protein expression to control the informational capacity of a neuron, it can 
be predicted that miRNA regulation will play a role in the micromanagement of this 
process.  Furthermore, it can be predicted that epigenetic factors, including alterations 
in DNA methylation, histone acetylation, and short RNA modulation, will play a 
major role in the phenotypic changes associated with many experimental drug 
therapies.  One such therapy, discovered by Bryan Kolb et al in 2007, involves 
simultaneous infusion of epithelial growth factor (EGF) and erythropoietin (EPO) 
into the contralateral ventricle following a motor cortex stroke (Kolb, et al., 2007).   
This drug therapy produces highly promising behavioural results, with test animals 
demonstrating a significant improvement in recovery compared to untreated animals.  
Even more impressive than the behavioural results was the induction of neurogenesis 
caused by this treatment – causing the lesion to fill in with newly-generated tissue.  
The authors also determined that the fresh tissue was not directly responsible for the 
behavioural improvement.  Instead, it appeared to be performing auxiliary processing 
that assisted the unaffected tissue to reorganise and reproduce the animal’s lost 
behavioural repertoire. 
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6 – Materials and Methods 
 
6.1 - Animals 
Male Long-Evans rats (N= 20), 120-150 days old at the beginning of the 
studies, were used as subjects. The rats were housed and maintained according to the 
regulations of the Canadian Council on Animal Care. Rats with motor cortex stroke 
were treated with EGF + EPO (n = 8) and compared with untreated animals (n = 8) 
and normal controls (n = 4). 
 
6.2 - Surgery 
Under isofluorane anaesthesia (3%), a rectangular hole was drilled into the 
frontal and parietal bones running from +3 to -4mm anterior/posterior to the Bregma 
and running laterally from 1.5 to 4.5mm from midline. The focal, permanent 
devascularisation (stroke) has been described in detail elsewhere (Gonzalez, 
Whishaw, & Kolb, 2003).  Briefly, the dura was removed and a sterile saline-soaked 
cotton swab was used to wipe the pia and attached blood vessels from the cortical 
surface. Surgery was performed on the left hemisphere for half of the test animals, 
and on the right hemisphere for the other half. Infusion cannulae (23 gauge) were 
implanted in the lateral ventricle (LV) ipsilateral to the preferred paw using skull 
coordinates 0.8mm anterior–posterior from the Bregma, 1.4mm lateral from the 
midline, and 3.5mm ventral from the skull surface. The cannulae were connected to 
filled, pre-tested, s.c. placed osmotic minipumps (Alzet, California, model 1007D) via 
coiled, flexible polyethylene tubing. Cannulae were filled with either vehicle 
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(artificial cerebral spinal fluid plus 0.1% bovine serum albumin) or with  aCSF and 
EGF (10 mg/mL) + EPO (1365 IU/mL). There was no mortality as a consequence of 
the surgeries.  For 24 h after the devascularisation, the animals were lethargic and 
sensitive to touch, after which they returned to their pre-surgical behaviour. 
 
6.3 – Tissue Collection 
Following a four-month recovery period, test animals were euthanized with an 
intraperitoneal injection of Euthansol (Schering-Plough Animal Health, Pointe-Claire, 
Québec).  Animals were decapitated and their neural tissue was collected by surgical 
removal of either the motor cortex (in the case of sham animals), the peri-infarct 
region (in the case of untreated animals with strokes), or the regenerated tissue plug 
(in the case of EGF/EPO treated animals, which was subsequently flash-frozen with 
liquid nitrogen.  Furthermore, in all animals, a region of the motor cortex contralateral 
to the lesion was collected for comparison.  All samples were subsequently stored at -
80°C. 
 
6.4 – miRNA microarray expression analysis 
Total RNA was extracted from harvested brain tissues using TRIzol Reagent 
(Invitrogen, Burlington, Ontario) according to the manufacturer’s instructions. 
miRNA microarray analysis was performed by LC Sciences (Houston, TX). Ten 
micrograms of total RNA were size-fractionated (<200 nucleotides) by using a 
mirVana kit (Ambion, Austin, TX). Poly-A tails were added to the RNA sequences at 
the 3' ends using a poly(A) polymerase, and nucleotide tags were then ligated to the 
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poly-A tails. The tagged RNAs were hybridized to  dual-channel microarray µParaFlo 
microfluidics chips (LC Sciences) containing 439 miRNA probes to rat and mouse 
miRNAs, and then labelled with tag-specific dendrimer Cy3 and Cy5 fluorescent 
dyes. Dye switching was performed to eliminate the dye bias. The melting 
temperature of the detection probes was balanced by incorporation of varying 
numbers of modified nucleotides with increased binding affinities. 
 Hybridization images were collected using a GenePix 4000B laser scanner 
(Molecular Devices, Sunnyvale, CA) and digitized using Array-Pro image analysis 
software (Media Cybernetics, Silver Spring, MD). The maximum signal level of 
background probes was 180. A miRNA detection signal threshold was defined as 
twice the maximum background signal. Normalization was performed with a cyclic 
LOWESS (locally-weighted regression) method to remove system-related variations 
(Bolstad, Irizarry, Astrand, & Speed, 2003). Data adjustments included data-filtering, 
log2 transformation, and gene centering and normalization. T-test analysis was 
conducted between control and E2-treated sample groups. miRNAs with p values < 
0.05 were selected for cluster analysis. The clustering analysis was performed with a 
hierarchical method and with average linkage and Euclidean distance metrics (Eisen, 
Spellman, Brown, & Botstein, 1998). 
miRNAs chosen for subsequent analysis were selected based on an arbitrary 
mean minimum cut-off value of 500 units of fluorescence from the microarray data, 
in order to remove data points that, while statistically significant, may lack biological 
impacts. 
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6.5 – Confirmation of a putative miRNA target 
To examine whether or not noggin is, in fact, functionally targeted by miR-
152, a 3′-untranslated region (UTR) segment of the nog gene corresponding to a 
region of 250 bp (nucleotides 948 to 1198 of the total transcript) of nog (accession no. 
NM_012990) was amplified by PCR from rat brain-derived cDNA using primers that 
included a XbaI and EcoRI tails on the 5′ and 3′ strands, respectively.  PCR products 
were restricted with both XbaI and EcoRI restriction endonucleases and then gel 
purified.  nog-3′-UTR was ligated into pGL3 firefly luciferase vectors (Promega) by 
using the XbaI site located immediately downstream of the stop codon of luciferase.  
HEK293 cells were transfected with the firefly luciferase UTR-report vector, 
control Renilla luciferase pRL-TK vector (Promega), and precursor miR-152 for the 
nog-3′-UTR construct using LipofectAMINE 2000 reagent according to the 
manufacturer's protocol (Invitrogen). Twenty-four hours after transfection, cells were 
lysed with a 1× passive lysis buffer and the activity of both Renilla and firefly 
luciferases was assayed using the dual-luciferase reporter assay system (Promega) 
according to the manufacturer's instructions. Data were normalized to (-) controls and 
equalized to the expression of renilla luciferase, and presented in RLU (relative 
luciferase units) 
 
6.6 – Western Blot analysis of Protein Expression 
Brain tissue lysates were prepared by homogenization of 50 mg of tissue in 
500 ml of lysis buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium 
deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 mg/ml each aprotinin, 
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leupeptin, pepstatin; 1 mM Na3VO4, 1 mM NaF), sonication, and incubation at 4˚C 
for 30 min. This was followed by centrifugation at 10,000 x g at 4˚C for 20 min. 
Extracts containing equal quantities of proteins were separated by SDS-PAGE on 
10% polyacrylamide gels and transferred to PVDF membranes. Membranes were 
probed with primary antibodies against Noggin (1:1000; Santa Cruz Biotechnology) 
MeCP2 (1:1000; Abcam), DNA methyltransferase 3a (DNMT3a) (1:1000; Abcam), 
DNA methyltransferase 3b (DNM3b) (216S, 1:500, Cell Signalling), and Bone 
Morphogenic Protein 4 (BMP4) (1:500; Santa Cruz Biotechnology). Alkaline 
phosphotase-coupled donkey anti-rabbit secondary antibodies were used for 
visualization.  Antibody binding was revealed by incubation with horseradish 
peroxidase-conjugated secondary antibodies (GE Healthcare) and the ECL Plus 
immunoblotting detection system (GE Healthcare). Chemiluminescence was detected 
by Biomax MR films (Eastman Kodak, New Haven, CT).  Signals were quantified 
using NIH ImageJ 1.63 Software and normalized to actin. The protein levels in the 
tissues of exposed animals were normalized relative to controls. Two technical 
replicates were used for each immunoblotting. 
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7 - Results 
  
7.1 – miRNA microarray expression analysis 
 7.1.1 – General Trends 
 Experimental stroke induced numerous changes in the miRNAome, in both 
the lesioned and unlesioned cortex when compared to shams.  Furthermore, 
EGF/EPO therapy as described by Kolb et al (Kolb, et al., 2007) caused its own 
distinct pattern of miRNAome activity, influencing a larger number of miRNAs to 
change their activity than the non-treated conditions. 
 Specifically, in the lesioned cortex of untreated animals in comparison to 
shams, 9 miRNAs were down-regulated while 9 different miRs showed up-regulation 
(Figure 3a).  In comparison, examination of the regenerated tissue plug with respect 
to shams revealed the up-regulation of 18 miRs, and the downregulation of 35 (Figure 
3b). 
 Comparisons directly between similar tissue types revealed a second subset of 
changes, with 3 miRs showing an increase and 11 showing a decrease in expression 
in the EGF/EPO treated lesion relative to the untreated lesion (Figure 4a).  
Examination of non-lesioned contralateral cortex revealed a similar pattern, with 8 
miRs overexpressed and 12 miRs underexpressed in the treated brains relative to the 
untreated (Figure 4b). 
 A third comparison was made within-brain, of both treated and untreated 
animals.  In the untreated condition, the lesioned cortex showed up-regulation of 4 
miRNAs when compared to its corresponding contralateral cortex (Figure 5a).  Upon 
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EGF/EPO treatment, this disparity between hemispheres increased to 14 up-regulated 
miRs and 16 down-regulated miRs (Figure 5b). 
 Among these lists, a subset of miRNAs was selected based on an arbitrary cut-
off value of 500 units of fluorescence (i.e. any miRNA showing less than 500 units of 
fluorescence in both tissue types under comparison was disregarded due to 
questionable biological impact of extremely low levels of circulating miRNA) and 
examined further. 
  
7.1.2 – Specific miRNAs of probable biological significance 
The following miRNAs showed fold changes greater than 2.0 
miR-199a showed increased expression levels in the non-lesioned motor 
cortex of untreated stroke animals when compared with unlesioned shams (fold 
change = 6.5, p = 0.03), and decreased expression levels in the non-lesioned motor 
cortex of treated animals when compared with the non-lesioned motor cortex of 
untreated animals (fold change = 26.7, p = 0.0007). 
 miR-199a* showed a highly significant increase in expression levels in the 
lesioned motor cortex of EGF/EPO treated animals when compared to the non-
lesioned contralateral cortex (fold change = 4.3, p = 0.005). 
miR-199b showed increased expression levels in the non-lesioned motor 
cortex of untreated stroke animals when compared with unlesioned shams (fold 
change = 5.9, p = 0.03), and decreased expression levels in the non-lesioned motor 
cortex of treated animals when compared with the non-lesioned motor cortex of 
untreated animals (fold change = 28.3, p = 0.002).  The microarray detected no 
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significant difference between unlesioned shams and the non-lesioned cortex of 
treated animals. 
miR-138 showed a highly significant elevation in expression level in the 
lesioned cortex of EGF/EPO treated animals when compared to unlesioned shams 
(fold change = 2.6, p = 0.009).  miR-138 was also showed highly significant elevation 
in the nonlesioned cortex of EGF/EPO treated animals when compared to unlesioned 
shams (fold change = 1.9, p = 0.002). 
 miR-214 showed a highly significant increase in expression in the lesioned 
cortex of EGF/EPO treated animals when compared to their non-lesioned cortex (fold 
change = 2.5 p = 0.004), and a significant decrease in non-lesioned cortex of stroked 
animals when compared to unlesioned shams (fold change = 3.0, p = 0.05).  
miR-152 showed a highly significant increase in expression levels in the 
EGF/EPO treated stroke lesions when compared to contralateral, non-lesioned tissue 
(fold change = 2.5, p = 0.003).  In untreated brains, however, miR-152 showed a 
smaller but still significant trend in the opposite direction, with a slight decrease in 
the peri-infarct when compared to contralateral nonlesioned tissue (fold change = 1.6, 
p = 0.04). 
 miR-21 was significantly up-regulated in both the non-lesioned (fold change = 
1.3, p = 0.05) and lesioned (fold change = 2.2, p = 0.02) cortex of EGF/EPO treated 
animals when compared to sham.  Furthermore, when comparing directly between the 
two hemispheres, miR-21 also showed a detectable increase in expression from the 
lesioned hemisphere to the non-lesioned hemisphere (fold change = 1.7, p = 0.05). 
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 miR-145 showed a highly significant increase in expression in the lesioned 
cortex of EGF/EPO treated animals when compared to their non-lesioned cortex (fold 
change = 2.0, p = 0.005).  It was significantly down-regulated in non-lesioned treated 
cortex when compared to unlesioned shams (fold change = 1.8, p = 0.02).  The 
microarray detected no significant difference in expression levels of miR-145 
between unlesioned shams and treated lesioned groups. 
 
7.1.3 – Specific miRNAs of possible biological significance 
 The following miRNAs showed a fold change less than 2, while achieving 
statistical significance by T-test. 
 miR-129-5p showed a highly significant decrease in expression in EGF/EPO 
treated animals, both in the non-lesioned cortex (fold change = 1.5, p = 0.002), and 
the lesioned cortex (fold change = 1.9, p = 0.0007), compared to shams.  This miRNA 
also showed a significant decrease in the non-lesioned cortex of EGF/EPO treated 
animals when compared to lesioned cortex (fold change = 1.4, p = 0.01). 
 miR-132 showed a significant increase in expression in the lesioned 
hemisphere of EGF/EPO treated animals when compared to the non-lesioned 
hemisphere (fold change = 1.5, p = 0.03) and unlesioned shams (fold change = 1.7, p 
= 0.01).  In untreated, lesioned animals, however, miR-132 showed a highly 
significant decrease in activity when compared to shams (fold change = 1.5, p = 
0.002). 
 miR-127 showed a significant decrease in expression in both the non-lesioned 
cortex (fold change = 1.4, p = 0.02) and the lesioned cortex (fold change = 1.6, p = 
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0.03) of EGF/EPO treated animals when compared to shams.  miR-127 showed no 
significant changes in expression level in other experimental treatments. 
 miR-107 showed a small but significant decrease in expression in the non-
lesioned hemisphere of EGF/EPO treated animals when compared to shams (fold 
change = 1.3, p = 0.05).  There were no significant alterations of miR-107 elsewhere. 
miR-124a showed a small but significant elevation of expression in the 
lesioned hemisphere of untreated animals when compared to shams (fold change = 
1.2, p = 0.02), and no significant changes in other conditions. 
 miR-9 is significantly up-regulated in the non-lesioned cortex of EGF/EPO 
treated animals when compared to the non-lesioned cortex of untreated animals (fold 
change = 1.2, p = 0.02).  Additionally, miR-9 shows an increase in expression in the 
non-lesioned cortex of treated animals when compared to the lesion/treated side as 
well (fold change = 1.2, p = 0.02) 
 
7.2– Confirmation of a putative miRNA target 
 
Figure 2 shows that miR-152 inhibited the luciferase activity from the 
construct with the Noggin-3′-UTR segment in a concentration-dependent manner.  
There was no change in the luciferase reporter activity when the cells were co-
transfected with negative control (scrambled oligonucleotides). No luciferase 
expression changes were seen when the cells were transfected with the plasmid 
lacking the Noggin-3′-UTR fragment. 
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7.3– Analysis of Protein Expression 
 
 Given the ability of miRNAs to affect the cellular phenotype by dramatically 
altering the translational activity of mRNA, it becomes highly relevant to observe the 
activity of the proteome in response to any alterations in miRNA activity.  With that 
relationship in mind, this study examined the activity of two subsets of proteins 
through Western Blot analysis – Noggin and BMP4, the former of which is a putative 
target of miR-152.  The second group of proteins analysed in this manner were three 
key DNA methylation proteins, DNMT3a, DNMT3b and MeCP2. This was done to 
examine the state of a second epigenetic regulatory pathway in response to EGF/EPO 
therapy, as the activity of all types of epigenetic regulators are intrinsically linked 
(Guil & Esteller, 2009). 
 
7.3.1 – Noggin and BMP4 
Noggin was not significantly down-regulated in the lesioned cortex of rats 
with a stroke (92% relative to control), but was significantly reduced in lesioned 
cortex of EGF/EPO treated animals (83% relative to control).  BMP4 levels showed a 
significant decrease in both lesioned (85% relative to control) and treated-lesioned 
conditions (42% relative to control) (Figure 6) 
 
7.3.2 – MeCP2 and de novo DNA Methyltransferases 
 The expression levels of several key methylation proteins were affected both 
by stroke and stroke coupled with EGF/EPO therapy.  MeCP2, methyl CpG binding 
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protein, was significantly under-expressed in both lesioned (79% control activity) and 
EGF/EPO treated lesioned cortex (68% control activity).  Both treated and untreated 
non-lesioned cortex showed no significant change from shams. (Significant effect of 
LESION, no significant effect of TREATMENT) (Figure 7).  DNMT3a was 
significantly up-regulated in EGF/EPO treated lesioned cortex (134% control), and 
showed non-significant variation in all other conditions.  DNMT3b was significantly 
down-regulated in untreated animals, both in the non-lesioned cortex (80% control) 
and the lesioned cortex (72% control).  In treated animals, this was mirrored in the 
lesioned cortex (83% control), but in the non-lesioned cortex, DNMT3b was over-
expressed (118% control). (Figure 8) 
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8 – Discussion  
 
The results of this study, in general, demonstrate the existence of a large 
epigenetic component to the regulation of neural tissue in the months following a 
stroke, and also, that the therapeutic benefit of EGF/EPO drug therapy appears to 
induce an additional epigenetic effect above and beyond that of a stroke. Clearly, this 
study shows that in the brain, an organ heavily dependent on precisely controlled 
gene expression for normal function (learning and memory, synaptic outgrowth and 
plasticity, regulation of its high metabolic demands), abnormal function likewise taps 
into the mechanisms of epigenetic regulation.  This study indicates a number of 
potential effects of both stroke and EGF/EPO therapy, as evidenced both by the 
miRNA microarray and the subsequent Western Blot analysis of several key proteins 
of interest, a significant finding of the current work. 
 
8.1 – miRNA microarray expression analysis 
 8.1.1 – General Trends 
 The behaviour of the miRNAome in this study supports the prediction that 
EGF/EPO therapy taps into and enhances the pre-existing epigenetic mechanism 
already at work in the recovering brain.  However, quite intriguingly, it appears that a 
great deal of the miRNA changes at work in the untreated brain are either de-
activated or superseded by the treatment, as not all of the miRNAs on the ‘untreated 
brain’ lists are represented on the corresponding treated brain list.  This in itself 
presents questions regarding the mechanisms of EGF/EPO based miRNAome 
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regulation to be examined in future work.  Additionally, when considering the effects 
of EGF/EPO therapy, it is important to remember the high likelihood that the 
molecular effects of this therapy on brain tissue are not limited to miRNA / DNA 
methylation changes, as EGF (Higashiyama, et al., 2008) and EPO (Arcasoy, 2008) 
are both known to directly induce gene expression through transcription factor 
mediated pathways. 
 Figure 3a shows a comparison between lesioned tissue and untreated shams in 
both conditions.  Of note is the difference in magnitude of the number of up-regulated 
vs. down-regulated miRs.  Addition of EGF/EPO causes the number of up-regulated 
miRs to change from 9 to 18, a two-fold increase, whereas the number of down-
regulated miRs changes from 9 to 35 – nearly a four-fold increase.  This suggests that 
one of the mechanisms of EGF/EPO therapy in the lesioned hemisphere is a net 
global suppression of miRNA activity.  Given that the mechanism of miRNA 
regulation is a suppression of gene expression in general, this is consistent with the 
prediction that EGF/EPO therapy is activating or enabling a wave of gene expression 
leading to the growth of new tissues.   
 The behaviour of the miRNAome in the direct comparison of treated and 
untreated brain regions (Figure 4) follows this trend, with a net down-regulatory 
effect present in both treated and untreated.  However, it should also be noted that the 
expression patterns between the lesioned and unlesioned hemispheres were quite 
different, involving effectively two different subsets of the miRNAome.  
Additionally, EGF/EPO therapy appears to have induced a greater degree of up-
regulation in the nonlesioned hemisphere.  This could be a potential indication of 
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slightly ‘tighter’ control over gene expression in the nonlesioned cortex, possibly 
because this tissue is effectively uninjured – too much de-repression of expression in 
this region could lead to uncontrolled cell division and growth, which could bring 
about a deleterious phenotype. 
 The within-brain comparison showed the most dramatic difference between 
untreated and treated brains (Figure 5), a trend which highlights a large difference in 
neural EGF/EPO response depending on the injury status of the tissue.  This result is 
support for the conclusion that the cellular environment and molecular status (in this 
case, injury signals) of the brain plays a major role in the epigenetic effects of a given 
drug therapy.  What exactly is inducing the changed response between injured and 
non-injured tissue remains unknown, though due to the self-regulating ability of many 
miRNA clusters, it is possible that the miRNA profile of a given brain region directly 
influences its miRNAome response to drug therapy. 
  
8.1.2 – Specific miRNAs 
Of the miRNAs identified by the microarray, those having pre-existing 
confirmed mRNA targets are examined in greater detail here.  A number of these 
miRNAs showed very small fold changes that, while determined to be statistically 
significant by the microarray, may be of minimal biological impact.  The following 
section ranks miRNAs by the magnitude of their respective fold changes.  A 
microRNA with a fold change of <2 is indicative of a possible Type I error, though 
speculation regarding its role in the biological context of EGF/EPO and untreated 
stroke remains relevant. 
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8.1.2 – Specific miRNAs of probable biological significance 
 miR-199a and 199a* 
miR-199a and 199a* are generated from the complimentary strands of the 
same precursor molecule (Kim, et al., 2008) though the data from this study suggests 
that either elements of the neural environment or the phenotypic changes brought 
about by EGF/EPO therapy and neurogenic recovery influence the behaviour of the 
RISC complex while processing the pre-miR. Even though both miRs are under the 
influence of the same nuclear factors, including transcription levels, pri-miR 
processing and nuclear export, the cytoplasmic levels of the two miRs vary across 
experimental conditions.  A study by Kim et al (Kim, et al., 2008) presents an in-
depth analysis of the behaviour of miR-199a* in various tissues and cancer cell lines, 
and experimentally confirms its down-regulation of the MET proto-oncogene and its 
downstream signalling component ERK2.  Though their study focuses on the 
behaviour of miR-199a* as a possible tumour suppressor gene (and, in fact, shows 
that in an uninjured brain, miR-199a* is transcriptionally repressed), its behaviour in 
the context of an injured, EGF/EPO treated brain indicates that it could play a role in 
the regulation of EGF/EPO induced neurogenesis.  The increase of miR-199a* in the 
newly-generated tissue corresponds to a decrease in the levels of active MET, which 
is a proliferative factor.  This finding ssuggests that the altered regulation of miR-
199a* could be acting as a “braking” signal to the neurogenesis triggered by 
EGF/EPO therapy four months prior. 
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miR-199b 
Currently, miR-199b is not confirmed to exist in rats; however, the detection 
of a readable mmu-miR-199b signal by the LCS microarray shows that the mature 
sequence of miR-199b is present in the cytoplasm of rat brain cells. Human miR-199b 
has been confirmed to target LAMC2 (laminin gamma 2), an extracellular matrix 
glycoprotein, which plays a major role in cell migration and differentiation (Tanno, et 
al., 2006).  Laminins have long been known to play a critical role in promoting the 
outgrowth of neurites from adult neurons (Cowen & Gavazzi, 1998) in concert with 
growth factors.  The two distinct patterns of miR-199b regulation shown at four 
months post-lesion indicate that stroke and EGF/EPO therapy both have independent 
influence on the regulation of cellular adhesion molecules. Stroke appears to trigger 
an increase in miR-199b activity in the non-lesioned cortex; EGF/EPO therapy 
returns miR-199b levels to baseline.  Specifically, the 28-fold decrease of miR-199b 
expression in treated animals compared to their untreated counterparts suggests that 
the treated animals demonstrate de-repression of LAMC2 expression, promoting 
neurite outgrowth and plasticity in the non-lesioned cortex.  This could partially 
account for the finding by Kolb et al (Kolb, et al., 2007) which suggested that the 
newly generated cortical tissue’s role in functional recovery may be the promotion of 
reorganization and modification of pre-existing neural circuitry. 
miR-138 
 The observed changes in the expression pattern of miR-138 indicate that its 
effects are tied to the global changes induced by the combination of EGF and EPO, as 
no significant differences were observed in untreated animals.  It is interesting to note 
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that miR-138 was elevated in both hemispheres of treated animals’ brains, but to a 
higher extent in the lesioned cortex, which suggests that the lesion effect may 
modulate the magnitude of miR-138 alteration following its induction. 
 miR-138 has been confirmed to target telomerase reverse transcriptase 
(TERT) (Mitomo, et al., 2008), the catalytic subunit of the telomerase holoenzyme, 
which is responsible for maintenance of chromosomal telomeres.  TERT activity is 
associated with the maintenance of neural progenitor and stem cells in the brain, with 
depletions of TERT causing the development of abnormal brain function and 
behaviour in mice (J. Lee, et al., 2009).  The inverse correlation between TERT and 
stem cells suggests that an opposite miRNA expression pattern exists (i.e. lower 
levels of miR-138 causing de-repression of TERT activity), but it appears that at four 
months post-lesion and treatment, microRNA signalling is moving to repress TERT 
levels.  This may indicate that at the four-month timepoint, miR-138 is contributing to 
the array of antiproliferative signals in the newly-generated tissue, and in the brain at 
large.  It is also possible that increased miR-138 activity in the treated brain is 
operating as a protective mechanism to attenuate the hyperproliferation of activated 
neural stem cells. This outcome would prevent tumorgenesis, as high activity of 
TERT is a hallmark of the development of glioblastoma (Casalbore, et al., 2009). 
miR-214 
miR-214 is well-known in molecular oncology, targeting PTEN phosphotase 
(Yang, et al., 2008).  PTEN acts as an inhibitor of the PKB/Akt cell survival pathway 
(Song, Ouyang, & Bao, 2005).  The up-regulation of miR-214 in the peri-infarct 
region of treated animals suggests that the microRNAome is playing a key role in the 
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modulation of cell survival in the new neural tissue, in this case, by promoting 
antiapoptotic signalling to ensure the survival of the newly generated tissue. 
8.1.2k – miR-21 
 miR-21 is a particularly interesting microRNA to study in the context of the 
brain, as it is one of the most intensely studied of the onco-miRs (i.e., microRNAs 
that play a role in cancer).  It responded very strongly to EGF/EPO therapy during 
this study, and was up-regulated in both motor cortices of treated animals.  The array-
based detection of an additional significant difference in expression, with the lesioned 
cortex having a 1.66 fold increase on top of the increase seen in the nonlesioned 
cortex, is important.  It indicates that some element of the injury-specific effect of 
EGF/EPO likely operates on the miR-21 regulatory network, causing its highly 
elevated levels of expression in lesioned, treated tissue.   
miR-21 has been experimentally confirmed to target multiple mRNA 
transcripts, tropomyosin 1 T(PM1) (Zhu, Si, Wu, & Mo, 2007), serpin peptidase 
inhibitor, clade B (ovalbumin), member 5 (SERPINB5) (Zhu, et al., 2008), PTEN 
phosphotase (Meng, et al., 2006; Meng, et al., 2007), and programmed cell death 4 
(PCDC4) (Asangani, et al., 2008; Frankel, et al., 2008; Lu, et al., 2008; Zhu, et al., 
2008).  The role of many of these genes as tumour suppressors makes miR-21 of great 
interest in the study of cellular proliferation, since increases in miR-21 elevates the 
rate of cell division.  In addition, and relevant to the neurological context of this 
work, miR-21 targets Sprouty2 (SPRY2), an inhibitor of branching morphogenesis 
and neurite outgrowth (Sayed, et al., 2008). 
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TPM1 is an actin-binding protein known to stabilise microfilaments (Zhu, et 
al., 2007), which becomes down-regulated in cancerous conditions, leading to the 
generalised lack of morphology characteristic of neoplastic cells.  In a neural context, 
alterations of cellular form are highly significant, though the role that a myosin-
dependent protein plays in specific neural plasticity may not be relevant.  SERPINB5, 
which is also known as mapsin, is an oncologically-relevant serine proteinase 
inhibitor (Cao, et al., 2007).  Although to date, the exact biochemistry and biological 
function of this protein are unknown, expression levels of mapsin serve as a useful 
prognostic barometer in determining the severity of tumours (Zhu, et al., 2008). They 
are also implicated in the suppression of tumour growth, invasion and metastasis, the 
induction of tumour redifferentiation, and enhancement of cell sensitivity to apoptosis 
(Lockett, Yin, Li, Meng, & Sheng, 2006).  PTEN phosphotase controls a critical cell 
cycle checkpoint (Chu & Tarnawski, 2004), and plays a major role in the 
development of neuroma and glioma (Endersby & Baker, 2008).  The existing body 
of work surrounding PTEN as an antiproliferative agent in the brain would make it an 
excellent target for further study in EGF/EPO based effects on stroke recovery. 
Perhaps the most important phenotypic consideration of  miR-21 induction 
and the consequent down-regulation of all of its downstream antiproliferative 
regulatory targets is the indication that this epigenetic change appears to be sustaining 
a pro-proliferative cellular environment in both the lesioned and non-lesioned 
hemispheres. 
Apart from its obvious impacts on proliferation in the brain, miR-21 activity 
appears to be a potent regulator of plasticity as well, by repressing a repressor of 
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cellular outgrowths, Sprouty2.  Regulation of SPRY2 could be playing two roles in 
the post-stroke brain, as it induces two separate phenotypic effects, depending on the 
age of the neurons it is expressed in.  In immature neurons, SPRY2 overexpression 
will inhibit the plasticity and development of these neurons by preventing the growth 
of new neural processes (Gross, et al., 2007).  High levels of miR-21 based repression 
of this mediator in the lesioned cortex would permit the neural progenitors to develop 
more rapidly and more fully.  Conversely, in mature, differentiated neurons, high 
levels of SPRY2 correlate with neuronal apoptosis; low levels of SPRY2 correlate 
with neuronal survival (Gross, et al., 2007).  In both hemispheres of the post-lesioned 
brain, repression of SPRY2 would contribute to pro-survival signalling. 
The magnitude and breadth of miR-21 induction in EGF/EPO therapy indicate 
a potential side effect of this drug treatment – any enhancement of proliferative 
activity should be immediately examined for its oncogenic potential.  Growth factor-
based therapies may prove dangerous in this regard, though they give rise to an 
intriguing conundrum:  in the case of stroke, where the typical patient is elderly, is the 
behavioural and lifestyle improvement brought about by drug therapy worth the 
potential risk for future cancer?  Reconciling this “dilemma” depends on the timing of 
any potential carcinogenic induction – if growth factor therapy is shown to increase 
the risk of brain cancer 20 years post-treatment, it could serve as a very useful tool to 
increase the quality of life of an elderly stroke patient.  More rapid progression of 
potential cancers would be an important ethical issue to address when analysing the 
potential cost/benefit analysis of EGF/EPO stroke therapy. 
 
- 62 - 
 miR-145 
 The two different expression patterns of miR-145 taken in context suggest that 
the phenotypic changes induced by EGF/EPO contribute to the recovery of ‘normal’ 
levels of this microRNA in the lesioned hemisphere.  This implies that 
devascularisation followed by EGF/EPO treatment induces a depletion of miR-145 in 
the unlesioned cortex, or that stroke triggers a global depletion of miR-145, which is 
reactivated in the peri-infarct region by EGF/EPO therapy. 
miR-145 has been shown to target two different transcripts for down-
regulation – FLJ21308 (also known as Poly(ADP-ribose) polymerase 8 (PARP8)) 
(Kiriakidou, et al., 2004) and IRS1 (insulin receptor substrate-1) (Shi, et al., 2007).  
PARP8 is a member of the PARP superfamily of proteins, a diverse group of 
enzymes capable of poly(ADP-ribosyl)ation of nuclear proteins by virtue of the 
conserved PARP domain (Ame, Spenlehauer, & de Murcia, 2004).  Though the 
current structure and enzymatic role of PARP8 has not been determined to date, the 
more closely studied members of this family facilitate and contribute to DNA repair 
processes and, consequently, cell survival.  Interestingly, reduction of PARP activity 
by selective inhibition has been shown to provide some neuroprotective effects in 
models of mouse ischemia (Burkle, 2001), as a sharp increase in PARP activity 
appears to be a precursor to ischemic cell death.  However, the role of PARP in 
ischemia appears to be dependent on a variety of other factors, as a second study 
demonstrated that limited PARP activity in concert with maintenance of cellular 
levels of NAD+ in fact prevented reperfusion damage in the rat hippocampus 
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(Nagayama, et al., 2000).  Without further research into the specific function and 
mechanism of PARP8-mediated poly(ADP-ribosyl)ation, it is difficult to determine 
which side of the PARP-ischemia equation it contributes to. 
IRS1 is the major substrate insulin-like growth factor receptor (IGF-IR), and 
plays a major role in mitogenic signalling (Baserga, 2000), cell growth and cell 
differentiation (Shi, et al., 2007).  In a neuronal context, it appears that IRS-1 activity 
plays a major role in antiapoptotic signalling, by activation of PI3K, which in turn 
activates PKC and Akt/protein kinase B (PKB) (Zhao & Alkon, 2001).  
Consequently, it is possible that the mir-145 induced suppression of IRS1 plays a 
distinct role in the brain following treatment.  Similarly to the behaviour of miR-
199a*, miR-145 signalling appears to be suppressing proliferative and antiapoptotic 
signalling. This suggests that multiple aspects of the miRNAome are operating in 
concert to arrest the growth triggered by EGF/EPO four months prior. 
 
8.1.3 – Specific miRNAs of possible biological significance 
 miR-129-5p 
miR-129-5p has two confirmed mRNA targets, having been shown to 
decrease the activity of both EIF2C3 (eukaryotic translation initiation factor 2C, 3) 
and CAMTA1 (calmodulin binding transcription activator 1) (Liao, et al., 2008).  
This miRNA is induced in the contralateral nonlesioned cortex in both treated and 
untreated animals, indicating that the decrease in miR-129-5p levels is a feature of the 
neural environment induced contralateral to a motor cortex stroke.  As a result, it may 
play a role in the phenotypic changes associated with increases in neural plasticity 
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and re-distribution of neural function observed in the contralateral hemisphere.  The 
additional down-regulation of miR-129-5p in the lesioned, treated cortex is a possible 
direct effect of EGF/EPO therapy. 
 EIF2C3 is a member of the Argonaute family of proteins (Sasaki, Shiohama, 
Minoshima, & Shimizu, 2003), which, as discussed previously, are critical 
components of the RISC / Dicer complex (Liao, et al., 2008).  De-repression of this 
protein in the non-lesioned cortex would result in the modulation of the behaviour of 
all Dicer-mediated short RNA activity, which may be a contributing factor in the 
plastic changes seen in the recovering brain.  Though the specific role of EIF2C3 in 
short RNA processing are not known at this time, the miR-129-5p / EIF2C3 pathway 
has been implicated in the differentiation of human hematopoietic stem cells (Liao, et 
al., 2008).  This link may be relevant in a neural context due to the recent finding by 
Kozlowska et al (Kozlowska, et al., 2007). These authors generated a lineage of 
neural-like stem cells (dubbed HUCB-NSC) from hematopoietic umbilical cord 
progenitors.  It is possible that the modulation of short RNA signalling in the 
contralateral cortex plays a role in neuronal cell fate, and during modulation of any 
potential stem cells that are endogenously present in the non-injured cortex.   
 CAMTA1, though relatively unstudied, has been shown to play a role in the 
induction of cell differentiation and cell cycle regulation (Nakatani, et al., 2004).  Its 
potential de-repression by decreases in miR-129-5p activity in the contralateral cortex 
could play an additional role in compensatory plasticity by modulating the 
differentiation of any active neural progenitors in the contralateral cortex.  By de-
repressing EIF2C3 and CAMTA1, miR-129-5p may be promoting a pro-neuronal and 
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pro-survival phenotype for the growth of new tissue in the lesioned cortex, and 
potentially supporting alterations in neural plasticity in the non-lesioned one. 
miR-132 
 miR-132 is known to be a target of CREB (the cAMP response element 
binding protein), and it is also known to target p250GAP, a GTPase activating protein 
(Vo, et al., 2005).  The expression pattern of miR-132 indicates that EGF/EPO 
therapy induces increased expression of miR-132 in the lesioned cortex following a 
stroke, in contrast to the decreased levels of miR-132 found within the lesions of 
untreated animals. This drug-dependent response makes miR-132 an ideal candidate 
for further study as a downstream effect of EGF/EPO therapy. 
 CREB is considered a prototypical transcription factor in the brain, capable of 
responding to a variety of hormonal, electrical, and growth factor based signalling 
(Lonze & Ginty, 2002).  In a recent study, Vo et al identified a variety of CREB-
regulated targets implicated in neuronal plasticity, miR-132 among them (Vo, et al., 
2005).  They selected miR-132 for further study due to its high abundance in neurons 
and its responsiveness to neurotrophic signalling.  These authors discovered that 
overexpression of miR-132 induced sprouting of neuronal processes, and that 
inactivation of the miRNA reversed this process.  The study demonstrated that miR-
132 targets p250GAP for suppression, and consequently, that it increases neural 
plasticity, by inhibiting p250GAP / Rac / cdc42 regulated control of neurite 
outgrowth (Nakazawa, et al., 2003; Vo, et al., 2005).   
If EGF/EPO therapy induces increased plasticity in the peri-infarct region, this 
immediately raises questions about the role of p250GAP in the post-ischemic brain.  
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It is known that enhanced signalling in the peri-infarct region triggers excitotoxicity 
and the ischemic cascade.  In this case, it is possible that decreased miR-132 
signalling and subsequent enhancement of p250GAP behaviour acts as a 
neuroprotective buffer in the normal brain, by decreasing neural plasticity during 
phases when the peri-infarct region is vulnerable to excitotoxic damage (Di Filippo, 
et al., 2008).  Though beyond the scope of this work, an in-depth analysis of the 
temporal behaviour of miR-132 and p250GAP would reveal the nature of this 
regulation, and answer several key questions.  Does EGF/EPO enhance the 
neuroprotective benefit of p250GAP signalling at more acute timepoints?  When does 
the enhanced plasticity brought about by p250GAP suppression come into effect?  
Does this effect play a role in the function of the freshly-regenerated tissue (i.e., 
enhancing the activity of surrounding regions instead of directly replacing lost 
functions)? 
miR-127 
 miR-127 is down-regulated in both cortices as consequence of EGF/EPO 
therapy, regardless of the status of tissue injury.  miR-127 is transcribed from the 
anti-sense strand of the Rtl1/Peg11 gene, which encodes a polycistronic cluster of 
five pre-miRs (Davis, et al., 2005).  This gene is preferentially expressed in embryo, 
placenta, brain and skeletal muscle.  It appears to be highly regulated during 
embryonic imprinting, due to its ability to trans regulate (i.e. the paternal anti-Peg11 
miRNA cluster is capable of targeting and down-regulating the products of the 
maternal Rtl1/Peg11 gene).  Unfortunately, data on the activities of the Rtl/Peg11 
locus outside of imprinting do not exist.  Further exploration of its behaviour may 
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provide answers about the extent to which EGF/EPO mediated neurogenesis mimics 
neural development. 
 miR-127 also targets BCL6, which is best known as a proto-oncogene capable 
of down-regulating the p53 tumour suppressor (Saito, et al., 2006).  A reduction of 
the levels of miR-127, in this case, could contribute to proliferative signalling in the 
post-EGF/EPO brain. 
miR-107 
 miR-107 only shows a small alteration in expression levels, which only reach 
significance in the non-lesioned cortex of EGF/EPO treated animals.  This finding is 
evidence that EGF/EPO drug therapy induces specific epigenetic effects in uninjured 
tissue, in addition to any induction effect it has on injured and proliferating tissue.  It 
also suggests that the phenotypic effects of this therapy extend beyond the infarction 
itself.  It has been confirmed that miR-107 targets two mRNA transcripts – the NF1-
A transcription factor (Garzon, et al., 2007), and BACE1 (beta-secretase 1) (Wang, et 
al., 2008).  NF1-A is involved in a complex regulatory feedback loop involving miR-
223, miR-107, and C/EBPalpha, which directs granulopoiesis (Fazi, et al., 2005) in 
both a developmental and a carcinogenic context. The role it plays in the brain is 
unclear to date.  BACE1, on the other hand, has been implicated in Alzheimer’s-
related neurodegeneration (Wang, et al., 2008), with levels of miR-107 increasing 
over the course of the disease progression and causing a decrease in levels of BACE1.  
The very slight decrease of miR-107 levels in the non-lesioned treated cortex should 
therefore be examined very closely during any future clinical trials of this drug 
therapy. Any measureable or detectable alteration or change in the level of this 
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protein could be indicative of side effects related to AD-related dementia.  Indeed, 
this result supports the use of miRNA microarrays as potential predictors of 
pharmacological side effects before any drug therapies are moved from animal to 
human tests. 
miR-124a 
miR-124a is a constitutively expressed neural microRNA, generating some of 
the highest levels of raw fluorescent signal of any of the miRs revealed by the 
microarray analysis during this study.  These results are consistent with the literature, 
with studies indicating that high levels of miR-124a promote the expression of a 
neuronal mRNA phenotype (Conaco, Otto, Han, & Mandel, 2006).  This promotion 
of a neuronal phenotype involves the repression of, as the authors put it, ‘hundreds of 
nonneuronal transcripts’, to the extent that experimental induction of miR-124a 
causes HeLa cells to produce a strong neuronal profile.  The elevation of miR-124a 
seen in untreated peri-infarct tissue could be a result of increased pro-neuronal 
signalling that attempts to guide endogenous stem cells (as reported in (Jin, et al., 
2001)) toward a neuronal fate. It could also be a potential means of maintaining the 
brain’s nonproliferative state.  The alteration in miR-124a levels is not apparent in 
treated animals, which suggests that the neuronal differentiation forced by 
erythropoietin is independent of miR-124a-induced proneuronal signalling.  This may 
indicate that the role of miR-124a is more strongly related to maintenance of the 
neuronal phenotype in vivo, though this requires further study. 
miR-124a, in addition to its strong proneuronal effect, has a number of 
confirmed mRNA targets, which further illustrates its role in both neuronal 
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differentiation and neural plasticity in general (Karginov, et al., 2007).  One such 
target, VAMP3 (vesicle-associated membrane protein 3), is a component of the 
synaptic vesicle SNARE complex which specifically localises to endocytic 
compartments (Hu, Rickman, Carroll, & Davletov, 2004).  An increase in miR-124a 
could be linked to a decrease in synaptic vesicle plasticity, as a potential cause or 
effect of the decreased efficacy of neural signalling in the damaged tissue.  
Reductions in synaptic neurotransmitter re-uptake capability could contribute to a 
plasticity decrease in this manner.  
miR-9 
 miR-9 appears to be specifically induced in the non-lesioned cortex of 
EGF/EPO treated animals. It shows significant increases in this tissue when compared 
both to untreated tissue and the lesioned area in the same animals.  This suggests that 
a tissue-specific induction of miR-9 occurs in uninjured cortex. 
 miR-9 is known to target two mRNAs – granuphilin/SLP4 (Plaisance, et al., 
2006) and BACE1 (Hebert, et al., 2008).  The behaviour of granuphilin in the brain is 
only beginning to be understood, but it appears to play a role in the management of 
vesicle storage and exocytosis (Fukuda, 2003; Plaisance, et al., 2006).  miR-9 
mediated down-regulation of granuphilin in the non-lesioned cortex could, in this 
case, be influencing synaptic plasticity as a part of the global induction of plasticity 
and rearrangement of neural function that follows a stroke. 
 Similar regulation of BACE1 in this context is especially interesting, given the 
possible modulation of BACE1 in the nonlesioned EGF/EPO treated hemisphere, as 
already identified in this study (see section 8.1.2i).  An increase in miR-109 levels 
- 70 - 
would tend to decrease the levels of BACE1, which lends more support to the idea 
that it has potential to induce AD-like symptoms in the recovering patient.  Since the 
behaviour of BACE1 is modified by two miRNAs of interest, it would be an excellent 
candidate for further study, particularly given its role in neurodegenerative processes. 
 
 
8.2 – Alterations in DNA Methylation Machinery 
 
 Alterations in DNA methylation are directly linked with changes in neural 
phenotype, including synaptic regulation (Monteggia & Kavalali, 2009) and memory 
formation (Miller, et al., 2008).  During this study, both of the de novo 
methyltransferases, DNMT3a and DNMT3b, were examined to highlight any 
potential changes in methylation status.  Furthermore, MeCP2, a methyl CpG binding 
protein highly enriched in brain tissue, was examined to determine its role in 
methylation-dependent alteration of gene expression, as well as possible roles in 
neural plasticity. 
 
8.2.1 – MeCP2 
 MeCP2 plays a variety of roles in the brain that made it an important target to 
examine in this study.  The functional product of MeCP2 is a DNA binding protein 
which associates with methylated cytosines in the genome, and is thought to induce 
transcriptional repression of methylated targets.  Recent evidence shows that the role 
of MeCP2 may in fact be more complex, with studies indicating that it may act as 
either an activator or repressor in the hypothalamus (Chahrour, et al., 2008), and that 
it closely associates with several highly active promoter regions (Yasui, et al., 2007).  
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MeCP2 is highly expressed in the mammalian central nervous system.  It is 
preferentially expressed in neurons as compared to glia (Monteggia & Kavalali, 
2009), and has a neuronal morphology-dependent pattern of expression, showing a 
relative increase in protein level from immature to post-mitotic neurons (Kishi & 
Macklis, 2004; Matarazzo, et al., 2004).  The work of  Kishi et al (Kishi & Macklis, 
2004) showed that MeCP2 plays a major role in determining a neuronal fate, both in 
development and in the differentiation of neural precursor stem cells.  This evidence, 
in concert with the   decrease in MeCP2 expression in both treated and untreated 
animals’ peri-infarct regions that was detected during this study, suggests that both 
the peri-infarct region and the regenerated cortical tissue are comprised to some 
degree of neural progenitors and stem cells.  This possibility is also consistent with 
the original finding by Kolb et al (Kolb, et al., 2007), in which the regenerated tissue 
was not organised into fully mature cortical tissue.  It is possible that the decreased 
levels of MeCP2 noted above are a result of increased numbers of neural precursors 
and partially-differentiated stem cells in the peri-infarct region or the regenerated 
tissue. 
 Moreover, the role of MeCP2 as a regulator of transcription clearly generates 
a significant phenotypic impact on the recovering brain.  Mutations and deletions in 
MeCP2 are thought to be the causal agent of Rett syndrome, one of the leading causes 
of mental retardation in females (R. Z. Chen, Akbarian, Tudor, & Jaenisch, 2001).  
This disorder, in which patients exhibit stereotypical symptoms of lower brain weight 
and reduced neuronal cell size but no obvious structural defects or signs of 
neurodegeneration, appears to be tied to both the developmental effects of MeCP2, 
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and its role in maintaining a mature phenotype in neurons.  A depletion of MeCP2 in 
adult neurons is sufficient to generate a Rett-like phenotype (R. Z. Chen, et al., 2001), 
and its restoration reverses the phenotype (Luikenhuis, Giacometti, Beard, & 
Jaenisch, 2004).  A number of recent studies have also implicated MeCP2 in 
synaptogenesis (Cohen, et al., 2003), and, more generally, as a key regulator of 
activity-dependent neuronal gene expression (Luikenhuis, et al., 2004). 
What does this mean in the brains of animals recovering from a stroke?  From 
the above findings, it appears that depletion of MeCP2 in post-mitotic neurons 
induces a functional deficit in neuronal activity and plasticity.  This functional deficit 
could partially explain the loss of behavioural capacity resulting from stroke in 
untreated animals, though detailed behavioural analysis would be required to 
determine the functional capacity of peri-infarct tissue four months post-lesion.  
Interestingly, the recent finding by Li et al (Y. Li, Lu, Keogh, Yu, & Wei, 2007)  
suggests that the similar levels of MeCP2 depletion result from two different causes.  
Given that erythropoietin is independently capable of stimulating angiogenesis and 
neuroprotection in the ischemic region, it is possible that the lower levels of MeCP2 
observed in treated animals are more closely tied to the immature anatomical 
phenotype of the regenerated tissue plug, but in untreated animals, more closely 
related to the aftermath of the ischemic damage. 
 
8.2.2 – DNMT3a and DNMT3b 
 The only significant change to DNMT3a levels during this study occurred in 
the peri-infarct region following EGF/EPO therapy, indicating that this phenotypic 
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change was linked with neurogenesis and neuronal differentiation.  Unlike DNMT1 
mentioned above, DNMT3a is a de novo methyltransferase – it is capable of 
methylating unmethylated CpG dinucleotides.  Activity of de novo methyltransferases 
is responsible for the establishment of new methylation patterns, which are capable of 
changing the phenotypic state of a given tissue (Hermann, Gowher, & Jeltsch, 2004).   
 The expression pattern of DNMT3a and DNMT3b in EGF/EPO treated 
animals is, at first glance, somewhat contradictory, with a simultaneous increase and 
decrease, respectively, in expression level.  However, a recent finding by Watanabe et 
al (Watanabe, Uchiyama, & Hanaoka, 2006) suggests that this finding is consistent 
with previous results about the behaviour of methyltransferases in a neural system.  
These authors reported a temporally-mediated transition between levels of the two 
enzymes in neural progenitor cells, with undeveloped cells showing a higher level of 
DNMT3b activity which is gradually replaced by DNMT3a as the cells developed.  
This transition is highly consistent with the results of this study as well as the original 
work by Kolb et al (Kolb, et al., 2007), where the over-expression of DNMT3a and 
under-expression of DNMT3b in the repaired peri-infarct tissue could be guiding the 
cells to a more fully differentiated phenotype. 
Though a role for de novo methylation in the brain has yet to be firmly 
established, one possibility presented by Hermann et al (Hermann, et al., 2004) is the 
potential for de novo methylation to contribute to formation and preservation of a 
‘snap shot’ of a gene’s current methylation state by modification of an equilibrium 
state with demethylation mechanisms.  Transient repression may be able to ‘mark’ 
certain regions of the genome for later application of more persistent methylation 
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(Thomassin, Flavin, Espinas, & Grange, 2001).  This would involve the possible 
creation of an epigenetic memory trace.  Given the very obvious phenotypic changes 
induced by EGF/EPO, it is possible that alterations of methyltransferase activity 
(especially the presumed increase in methylation caused by over-expression of 
DNMT3a) could be directly involved in either activating neural stem cells, directing 
them towards neuronal fates due to EPO-mediated signalling cascades, or causing 
these new neurons to ‘lock in’ their gene expression patterns. 
 In light of the ties between DNA methylation machinery, de novo 
methyltransferase activity, and methyl-CpG binding activity, it appears that the 
neurogenesis initiated by EGF/EPO drug therapy is modifying the epigenome of both 
the neural stem cells originating in the sub-ventricular zone (SVZ) and the new 
neurons which migrate into the former lesion site.  It is possible, at the four-month 
point, that the new tissue, though functional, is held either in a state of neural 
immaturity, or is still approaching a fully post-mitotic state.  The former is supported 
by the lack of cortical organisation found in the tissue plug. The latter is supported by 
the finding of decreased levels of MeCP2 (indicative of immature neurons) and the 
shift from a DNMT3b-dominated de novo methylation phenotype to a DNMT3a one.  
To date, the genetic and epigenetic profiles of EGF/EPO directed neurogenic tissue 
have not been fully established, nor have their temporal properties been elucidated.  
Future studies may reveal the exact nature of the alterations of the methyl-ome, 
leading to a greater understanding of the process of growth-factor induced 
neurogenesis at an epigenetic level. 
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8.3 – Confirming a putative miRNA target – miR-152 and Noggin 
 
There are no regulatory targets that have been confirmed for miR-152 to date.  
The trends observed for this microRNA – a relative decrease in the peri-infarct region 
of untreated animals and a relative increase in the peri-infarct region of treated 
animals, were sufficient reason to select miR-152 as a prospective miRNA for some 
additional study.  In order to determine the biological activity of miR-152, in silico 
analysis was carried out using the Sanger miRBase target prediction algorithm 
(Griffiths-Jones, 2006).  Genes of interest were selected from the list of putative 
targets.  A putative binding site of miR-152 was found on the 3’UTR of noggin, an 
extracellular antagonist of bone morphogenic proteins (Valenzuela, et al., 1995).  To 
confirm the activity of mir-152 on the noggin transcript, the 3’ untranslated region 
(3’UTR) of noggin was cloned, and ligated to the 3’ end of a luciferase reporter gene. 
The observed decrease of the luciferase/nogginUTR reporter construct shows 
that miR-152 targets the UTR of noggin in cells, and subsequently down-regulates its 
activity.  Initially discovered and characterised in Xenopus, noggin has been found to 
be expressed and active in the adult mammalian brain (Valenzuela, et al., 1995), 
where it has been implicated in adult neurogenesis (Colak, et al., 2008), as well as in 
memory formation and regulation in the hippocampus (Fan, Cai, Yang, Xu, & Zhang, 
2003).  Noggin acts as a specific antagonist of bone morphogenic proteins (BMPs) by 
interfering with their ability to bind to the bone morphogenic protein receptor 
(BMPR).  These BMPs are extracellular ligands, which transduce a signal through the 
BMPR to phosphorylate SMAD1, 5 and 8 (Colak, et al., 2008), which then influence 
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transcription through a cAMP mediated pathway.  It has been shown that adult 
neurogenesis and differentiation require the activity of bone morphogenic proteins.  
Thus, it is possible that a portion of EGF/EPO induced neurogenic activity could be 
caused by the translational suppression of noggin due to elevated levels of miR-152 
in the months following a stroke.   
It is clear from the results that a hypoxic lesion induces a long-term, if not 
permanent, reduction in cellular BMP4 levels.  Previous studies have shown that 
hypoxia results in a short-term increase in the circulating level of bone morphogenic 
proteins (C. Zhang, et al., 2006).  This finding, coupled with the other results of this 
study, suggest that the immediate response of the peri-infarct region is an 
overproduction of BMP, which is then reduced as the cell death and tissue damage 
resulting from the initial hypoxic insult reach an equilibrium point.  After the initial 
hypoxic insult, BMP levels then decrease.  It should be noted, although detected 
levels of BMP4 are still decreased in the EGF/EPO peri-infarct region, that noggin 
mediated suppression does not reduce levels of BMP.  Instead, it reduces BMP 
activity.  Noggin-mediated effects on BMP activity, as a result, would be 
undetectable by Western Blot testing (analysis?). 
A model can be proposed where miR-152 based suppression of Noggin 
functions to counteract the natural decrease in BMP activity following a stroke. 
Undoubtedly, the greater phenotypic change induced by EGF/EPO therapy is far 
more complex, since EGF/EPO therapy also appears to induce a dramatic reduction in 
BMP4 levels at 4 months.  By suppressing noggin, mir-152 could act as a de-
repressor of BMP activity, forcing a greater percentage of neural precursors towards a 
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neuronal rather than oligodendritic fate.  Alternately, increased BMP2/BMP4 activity 
in hypoxic cells could be inducing astrocyte differentiation in SVZ progenitor cells 
(Xin, Li, Chen, & Chopp, 2006).  This EGF/EPO induced modulation of mir-152 
could alter the cellular environment of the peri-infarct region, which directs the 
differentiation of neural precursor cells to endpoints that promote recovery;  either 
neuronal endpoints, which may be integrating into pre-existing circuitry, or 
astrocytes, which play a key neuroprotective role in the immediate response to brain 
trauma (Bazan, Marcheselli, & Cole-Edwards, 2005).  This possibility raises what 
could be a key point of investigation in future studies, since astroglial activity is only 
neuroprotective shortly following initial neural trauma.  In the long-term, astrocytes 
form glial scarring, which inhibits CNS regeneration, and is a possible explanation for 
the reduction of BMP4 levels at this distal time point.  TA detailed study of astrocytes 
in the days and weeks immediately following an infarction, as well as their 
modulation by EGF and EPO, should generate a far clearer image regarding their role 
in stroke recovery. 
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9 – Conclusions, General Trends, Future Outlook 
 
 This study admittedly only scratches the surface regarding the role of miRNA, 
and, more broadly, epigenetic regulation in the post-ischemic brain.  It is clear from 
the findings detailed above that the analysis of epigenetic regulation in the brain is an 
incredibly complicated field, given both the importance of exquisitely timed 
regulation of gene expression, and the self-regulating capability of miRNA.  Despite 
this complexity, this study reveals a very important and diverse array of changes in 
epigenetic regulation following a stroke, indicating a great deal of potential for future 
development of epigenetic mechanisms to pharmacologically influence the brain.  
Due to the ability of miRNA precursors to bypass the blood-brain barrier, their 
potential as a delivery method for neural gene therapy cannot be ignored.  
miRNA regulation and alterations of DNA methylation are clearly only single 
components of a complicated, dynamic process, considering the complexity and 
novelty of EGF/EPO mediated induction of neurogenesis.  Four months after the 
stroke and subsequent therapy, miRNAs are acting to promote both survival 
mechanisms (such as miR-214, miR-129-5p, miR-127, miR-21, and miR-152) and 
cell death mechanisms (miR-199b, miR145, miR-138, and miR-107).  This could 
represent an analogue of the ‘pruning’ mechanisms undergone by the infant brain 
during the developmental cycle, wherein a developing brain initially grows an 
overabundance of neurons, and then induces the death of over half of them, which 
constitutes a necessary developmental step.  Additionally, this study reveals what 
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may very well be a note of caution both in the pursuit of EGF/EPO based drug 
therapies and pharmacological intervention in the brain in general.  Specific to this 
therapy, the regulatory impact on potential neurodegenerative mechanisms will 
necessitate careful monitoring of patients undergoing such a drug therapy, as well as 
careful consideration of the risk/benefit ratio.  More generally, by revealing a 
connection between drug therapy, epigenetic regulation and potential disease 
processes, this study confirms the validity of using epigenetic methods both to 
analyse the functional mechanisms of experimental drug therapies and direct future 
research into what the potential side effects of gene therapy may be. 
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Figure 1. Schematic representation of the biogenesis and mode of action of microRNA.  miRNA primary 
transcripts (pri-miRNAs) are transcribed from either miRNA genes or spliced from the introns of protein 
coding genes (not shown), whereupon they are processed by Pasha and Drosha to generate pre-miRNAs.  
Pre-miRNA is exported from the nucleus by the Exportin-5 enzyme, and processed by Dicer, forming the 
miR-anti-miR duplex.  Through the action of an unidentiﬁed enzyme, temporarily named unwindase, and 
the members of the RNA-induced silencing complex (RISC), mature miRNAs are incorporated into the active 
RISC holoenzyme.  Based on the complimentarity of the miRNA to the 3’UTR of its target transcripts, the 
mRNA is either immediately cleaved and degraded, or transported to p-bodies for disposal.
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Figure 2. Normalised, equalised luminescence data, showing a decrease in the expression level of a 
luciferase-noggin3’UTR hybrid in HEK293 cells under the influence of increasing transfection concen-
trations of miR-152 precursors and negative control. 
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Figure 3. miRNA microarray analysis.  Figure 3a (left) shows changes in miRNA expression in stroke tissue 4 
months post-lesion compared to shams.  Figure 3b (right) shows changes in miRNA expression in stroke tissue 
treated with EGF/EPO 4 months post-lesion compared to shams.
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Figure 4. miRNA microarray analysis.  Comparison of similar brain regions 
between untreated and EGF/EPO treated animals.  4a shows the changes 
in miRNA expression in the lesioned cortex, while 4b shows changes in 
miRNA expression in the nonlesioned cortex.
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Figure 5. miRNA microarray analysis.  Direct side-by-side comparison of diﬀerences in miRNA expression within a 
single experimental animal.  Figure 5a (left) shows a comparison between the lesioned and nonlesioned 
hemisphere of an untreated animal, while ﬁgure 5b (right) shows a comparison between lesioned and 
nonlesioned tissue in an EGF/EPO treated animal.
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Figure 6.  Representative Western immuno-blot images, showing untreated (A) and treated (B) con-
ditions, indicative of levels of noggin and BMP4 in the peri-infarct region (1) compared to the contra-
lateral region in the same animals (2), as well as shams (3).  Graphs show noggin / BMP4 as a per-
centage of controls, +/- standard deviation. 
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Figure 7 - Percentage variation in the levels of MeCP2 across multiple 
conditions with respect to shams (CT).  Data shown is percentage of 
controls + / - standard deviation. 
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Figure 8 - Percentage variation in the levels of de novo methyltransferases DNMT3a and DNMT3b 
across multiple conditions with respect to shams (CT).  Data shown is percentage of controls + / -  
standard deviation. 
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